



(11) **EP 2 364 968 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
14.09.2011 Bulletin 2011/37

(51) Int Cl.:
C07D 209/34 ^(2006.01) **A61K 31/404** ^(2006.01)
A61P 35/04 ^(2006.01)

(21) Application number: **11158863.8**

(22) Date of filing: **06.06.2007**

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30) Priority: **08.06.2006 EP 06115159**

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
07729916.2 / 2 029 533

(27) Previously filed application:
06.06.2007 EP 07729916

(71) Applicants:
• **BOEHRINGER INGELHEIM INTERNATIONAL GMBH**
55216 Ingelheim am Rhein (DE)
Designated Contracting States:
AT BE BG CH CY CZ DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
• **Boehringer Ingelheim Pharma GMBH & CO. KG., .**
55216 Ingelheim am Rhein (DE)
Designated Contracting States:
DE

(72) Inventors:
• **Sieger, Peter**
8841 Mittelbiberach (DE)
• **Rall, Werner**
88441 Mittelbiberach (DE)
• **Linz, Guenter**
88441 Mittelbiberach (DE)
• **Pop, Mihaela**
1060 NX Amsterdam (NL)
• **Mazurek, Jaroslaw**
2563 AV Den Haag (NL)

(74) Representative: **Hammann, Heinz**
Boehringer Ingelheim Pharma GmbH
CD-Patents
Binger Straße 173
55216 Ingelheim am Rhein (DE)


Remarks:

This application was filed on 18-03-2011 as a divisional application to the application mentioned under INID code 62.

(54) **Salts and crystalline salt forms of an 2-indolinone derivative**


(57) The present invention relates to new salts and crystalline salt forms of an indolinone derivative selected from citrate, tartrate, lactate, glycolate, gentisate, mandelate and salicylate of the formula (I)

EP 2 364 968 A1



and which have valuable pharmacological properties, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament.

Fig. XXI




Description

[0001] The present invention relates to new salts and crystalline salt forms of an indolinone derivative, namely of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, which have valuable pharmacological properties, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament.

Background to the invention

[0002] The compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone is known from WO 01/27081 and has the following chemical structure, depicted below as Formula (I)



[0003] Furthermore, the monoethanesulfonate salt of this compound is known from WO 04/13099 in its crystalline hemihydrate form, as well as a process for its manufacture.

[0004] The above mentioned patent applications further disclose the use of this compound or its monoethanesulfonate salt for the preparation of pharmaceutical compositions intended especially for the treatment of diseases characterized by excessive or abnormal cell proliferation.

[0005] Furthermore, WO 04/17948 discloses the use of this compound for the preparation of pharmaceutical compositions for the treatment of immunologic diseases or pathological conditions involving an immunologic component.

Summary of the invention

[0006] The aim of the present invention is to provide new salts and crystalline salt forms of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone as such which are characterized by advantageous physicochemical properties.

[0007] Another object of the invention is to provide new salts and crystalline salt forms of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone as such which are characterized by unexpected, new pharmacological properties.

Detailed description of the invention

[0008] The invention relates to a process for the preparation of the new salts and crystalline salt forms of the compounds of formula (I), optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates, and optionally to the hydrates and/or solvates thereof.

Process for the preparation of the salts

[0009] In the process according to the invention the free base of the compound of formula (I) is dissolved in a suitable solvent, such as 2,2,2-trifluoro-ethanol. The acid used for the crystallization is dissolved as well in a suitable solvent, such as 2,2,2-trifluoroethanol/water (50:50) or water (depending on the acid). The free base of the compound of formula (I) is then mixed with the acid at a predetermined base /acid molar ratio, which is selected from 1:1 or 2:1 depending on the acid. Then, the solvent is evaporated under reduced pressure. After evaporation of the solvent has occurred, a suitable crystallization solvent is added to the reaction mixture, and the reaction mixture is slowly heated up to 50°C. Suitable solvents for the crystallization are tetrahydrofurane, dichloromethane, water, methanol, n-butylacetate, 1,2-dimethoxyethane, 2,2,2-trifluoroethanol (TFE)/water = 8:2, acetone/ dimethylsulfoxide (DMSO) = 8:2, chloroform, acetonitrile, ethanol, 1-methyl-2-pyrrolidinone (NMP)/water = 80:20, propyl acetate, tert. butanol, 1,4-dioxane, ethyl acetate, propionitrile, di-isopropyl ether, tert. butylethyl ether, ethanol/water = 80:20, nitrobenzene, cyclohexanone, ethyl phenyl ether, 2 - nitropropane, tert. butylmethyl ether and isobutanol. After staying for about 30 minutes at 50°C, the reaction mixture is slowly cooled down to a suitable crystallization temperature, which is for example between 20°C or 3°C. The reaction mixture stays at this temperature until enough crystals are formed, which can then be collected, for example by filtration.

[0010] The process is illustrated by the following example of manufacturing process of the salts and crystalline salt forms, as can be done in parallel in 96 well assay plates (maximum volume of each well is about 200 µl).

[0011] Approximately 1 g of the free base of the compound of formula (I) is dissolved in 10 ml of 2,2,2-trifluoroethanol. The acids used to prepare the salts are dissolved in 2,2,2-trifluoroethanol/water (50:50) or just in water as far as the L-aspartic acid is concerned. Each well of the 96 well plates is loaded with the free base of the compound of formula (I) as dissolved in 2,2,2-trifluoroethanol and with the acid as dissolved in the mixture of 2,2,2-trifluoroethanol/water (50:50) or just in water as far as the L-aspartic acid is concerned, such that the molar ratio of the compound of formula (I) to the respective acid is set according to the information given in Table 1 under "ratio base/acid". The 96 well plates are then placed in a vacuum chamber (1 kPa) at room temperature for 24 h in order to evaporate the solvent. Afterwards, different solvents are added in each well according to the information given in Table 1 under "crystallization solvent", and the well plates are sealed and heated up to 50 °C at a heating rate of approx. 5 °C/min. The plate stays then for an additional 30 minutes at 50 °C. Afterwards, the plate is cooled at a cooling rate of 5°C/h to a final temperature of 3 or 20 °C according to the information given in Table 1 under "T_{final}[°C]". At this temperature, the plates remain for a holding time of 24 h. The plates are then opened and the solids are collected by filtration.

Table 1: Conditions for the preparation of the different salts of the compound 3-Z-[1-(4-(N-((4-methylpiperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone

salt form abbreviation	salt form full name	used acid	ratio base/acid	crystallization solvent	T _{final} [°C]
HCl1	chloride, form I	hydrochloric acid	1:1	tetrahydrofurane	20
HCl2	chloride, form II	hydrochloric acid	1:1	dichloromethane	3
HBr2	bromide, form II	hydrobromic acid	1:1	water	20
HBr7	bromide, form VII	hydrobromic acid	1:1	methanol	3
HBr8	bromide, form VIII	hydrobromic acid	1:1	n-butylacetate	20
Pho1	phosphate, form I	phosphoric acid	1:1	1,2-dimethoxyethane	20
Pho2	phosphate, form II	phosphoric acid	1:1	TFE*/water = 8:2	3
Sul1	sulfate, form I	sulfuric acid	1:1	acetone/ DMSO*=8:2	3
Sul5	sulfate, form V	sulfuric acid	1:1	chloroform	3
Sul6	sulfate, form VI	sulfuric acid	2:1	1,2-dimethoxyethane	20
Sul7	sulfate, form VII	sulfuric acid	2:1	acetonitrile	3
Mes1	mesylate, form I	methanesulfonic acid	1:1	ethanol	20

EP 2 364 968 A1

(continued)

	salt form abbreviation	salt form full name	used acid	ratio base/acid	crystallization solvent	T _{final} [°C]
5	Eds1	edisylate, form I	ethanedisulfonic acid	1:1	methanol	3
	Eds2	edisylate, form II	ethanedisulfonic acid	1:1	1,2-dimethoxyethane	3
10	Eds3	edisylate, form III	ethanedisulfonic acid	1:1	chloroform	20
	Eds5	edisylate, form V	ethanedisulfonic acid	1:1	NMP*/water=80:20	20
15	Eds6	edisylate, form VI	ethanedisulfonic acid	1:1	propyl acetate	20
	Ise1	isethionate, form I	isethionic acid or 2-hydroxyethanesulfonic acid	1:1	tert. butanol	20
20						
	Ise2	isethionate, form II	isethionic acid or 2-hydroxyethanesulfonic acid	1:1	1,4-dioxane	20
25						
	Ise4	isethionate, form IV	isethionic acid or 2-hydroxyethanesulfonic acid	1:1	ethyl acetate	20
30						
	Ise5	isethionate, form V	isethionic acid or 2-hydroxyethanesulfonic acid	1:1	propionitrile	20
35						
	Bes1	besylate, form I	benzenesulfonic acid	1:1	methanol	20
	Bes3	besylate, form III	benzenesulfonic acid	1:1	ethyl acetate	20
40	Bes5	besylate, form V	benzenesulfonic acid	1:1	tert. butanol	20
	Tos1	tosylate, form I	p-toluenesulfonic acid	1:1	1,2-dimethoxyethane	5
45	Tos2	tosylate, form II	p-toluenesulfonic acid	1:1	water	3
	Cas2	camphorsulfonate, form II	camphor-10-sulfonic acid	1:1	propionitrile	3
50	Cas3	camphorsulfonate, form III	camphor-10-sulfonic acid	1:1	ethyl acetate	20
	Cas5	camphorsulfonate, form V	camphor-10-sulfonic acid	1:1	propionitrile	20
55	Cas12	camphorsulfonate, form XII	camphor-10-sulfonic acid	1:1	1,2-dimethoxyethane	20

EP 2 364 968 A1

(continued)

	salt form abbreviation	salt form full name	used acid	ratio base/acid	crystallization solvent	T _{final} [°C]
5	Nds3	naphthalene-1,5-disulfonate, form III	naphthalene-1,5-disulfonic acid	1:1	di-isopropyl ether	3
	Nds5	naphthalene-1,5-disulfonate, form V	naphthalene-1,5-disulfonic acid	1:1	propionitrile	20
10	Cit1	citrate, form I	citric acid	1:1	1,4-dioxane	3
	Cit2	citrate, form II	citric acid	1:1	methanol	20
	D-Tar1	D-tartrate, form I	D-tartaric acid	1:1	ethanol	3
15	L-Tar1	L-tartrate, form I	L-tartaric acid	1:1	tert. butylethyl ether	20
	D-Tar2	D-tartrate, form II	D-tartaric acid	2:1	propionitrile	3
	L-Tar2	L-tartrate, form II	L-tartaric acid	2:1	ethyl acetate	20
20	Fum1	fumarate, form I	fumaric acid	1:1	ethanol/ water=80:20	3
	Fum3	fumarate, form III	fumaric acid	2:1	methanol	3
	Mae1	maleate, form I	maleic acid	1:1	propionitrile	20
25	L-Lac1		L-lactic acid	1:1	propyl acetate	20
	Glc1	glucolate, form I	glycolic acid	1:1	propionitrile	3
	Gly1	glycinate, form I	glycine	1:1	nitrobenzene	3
30	L-Mal1	L-malate, form I	L-malic acid	1:1	propionitrile	3
	D-Mal1	D-malate, form I	D-malic acid	1:1	propionitrile	3
	L-Mal2	L-malate, form II	L-malic acid	1:1	dichloromethane	3
	L-Mal3	L-malate, form III	L-malic acid	1:1	propyl acetate	20
35	D-Mal3	D-malate, form IV	D-malic acid	2:1	cyclohexanone	20
	Mao1	malonate, form I	malonic acid	1:1	methanol	20
	Mao2	malonate, form II	malonic acid	1:1	propyl acetate	3
40	Mao3	malonate, form III	malonic acid	2:1	1,4-dioxane	3
	Mao4	malonate, form IV	malonic acid	2:1	ethyl acetate	20
	Mao6	malonate, form VI	malonic acid	2:1	methanol	3
	Suc1	succinate, form I	succinic acid	1:1	methanol	3
45	Suc2	succinate, form II	succinic acid	1:1	ethyl phenyl ether	20
	Suc3	succinate, form III	succinic acid	1:1	acetone/ DMSO*=8:2	3
50	Oxa3	oxalate, form III	oxalic acid	1:1	1,2-dimethoxyethane	20
	Oxa5	oxalate, form V	oxalic acid	1:1	NMP*/water=80:20	20
55	Oxa6	oxalate, form VI	oxalic acid	2:1	propionitrile	3

(continued)

salt form abbreviation	salt form full name	used acid	ratio base/acid	crystallization solvent	T _{final} [°C]
Gen1	2,5-dihydroxybenzoate form I	gentisic acid or 2,5-dihydroxybenzoic acid	1:1	2 - nitropropane	3
Gen11	2,5-dihydroxybenzoate form XI	gentisic acid or 2,5-dihydroxybenzoic acid	1:1	1,2-dimethoxyethane	20
Cam2	camphorate, form II	camphoric acid	1:1	tert. butylmethyl ether	20
Cam3	camphorate, form III	camphoric acid	1:1	propyl acetate	3
Ben2	benzoate, form II	benzoic acid	1:1	acetone/DMSO*=8:2	3
Ben3	benzoate, form III	benzoic acid	1:1	propyl acetate	3
Man1	mandelate, form I	S-(+)-mandelic acid	1:1	methanol	3
Sac3	saccharinate, form III	saccharine	1:1	1,2-dimethoxyethane	3
Sac5	saccharinate, form V	saccharine	1:1	water/DMSO*=8:2	3
Sal1	salicylate, form I	salicylic acid	1:1	water	3
Sal2	salicylate, form II	salicylic acid	1:1	1,2-dimethoxyethane	20
L-Asp1	L-aspartate, form I	L-aspartic acid	1:1	1,2-dimethoxyethane	3
L-Asp2	L-aspartate, form II	L-aspartic acid	1:1	nitrobenzene	20
Xin1	xinafoate, form I	1-hydroxy-2-naphthoic acid	1:1	isobutanol	3
Asc1	ascorbate, form I	ascorbic acid	1:1	1,4 - dioxane	20
Asc3	ascorbate, form III	ascorbic acid	1:1	acetonitrile	3
Asc4	ascorbate, form IV	ascorbic acid	1:1	methanol	3
* TFE = 2,2,2-trifluoroethanol * DMSO = dimethylsulfoxide * NMP = 1-methyl-2-pyrrolidinone					

[0012] A preferred embodiment according to the invention thus relates to the preparation of the new salts and crystalline salt forms of the compound in accordance with formula (I) as specified hereinbefore.

[0013] In another embodiment, the invention relates to solutions containing the compound of formula (I) dissolved or suspended, preferably dissolved in a solvent. In a preferred embodiment, the solvent is an alcohol, preferably 2,2,2-trifluoro-ethanol.

[0014] In particular, the invention relates to specific crystalline forms of the compound of formula (I), which are discussed and characterized in detail below.

[0015] Analytical methods for the characterization of the salts

[0016] The harvested crystals may be characterized by X-ray powder diffraction and thermal analysis (DSC and in some cases also TGA). If suitable single crystals grow, single crystal X-ray structure analysis may be performed. The following equipment was used to characterize the crystalline salts forms.

X-ray powder diffraction (= XRPD)

[0017] XRPD patterns were obtained using a high throughput XRPD set-up. The plates were mounted on a Bruker GADDS diffractometer equipped with a Hi-Star area detector. The diffractometer was calibrated using Silver Behenate for the long d-spacings and corundum for the short d-spacings.

[0018] The data collection was carried out at room temperature using monochromatic CuK α radiation in the region of 2 θ between 1.5 and 41.5°. The diffraction pattern of each well was collected with an exposure time of 3 - 4 minutes.

Single crystal X-ray structure analysis

[0019] Suitable single crystals were selected and glued to a glass fibre, which is mounted on a X-ray diffraction goniometer. X-ray diffraction data were collected for the mounted crystals at a temperature of 233 K using a KappaCCD system and MoK α radiation generated by a FR590 X-ray generator (Bruker Nonius Delft, The Netherlands). Unit-cell parameters and crystal structure were determined and refined using the software package maXus (Mackay et al., 1997). Thermal analysis (DSC and TGA)

[0020] Melting properties were obtained from differential scanning calorimetry (= DSC) thermograms recorded on a DSC822e (Mettler-Toledo GmbH, Switzerland). The DSC822e was calibrated for temperature and enthalpy with a small piece of indium ($T_{fus} = 156.6^\circ\text{C}$, $\Delta H_{fus} = 28.45\text{ J/g}$). Samples were sealed in standard 40 μl aluminium pans and heated in the DSC from 25 to 300 $^\circ\text{C}$ with a heating rate of 20 $^\circ\text{C}/\text{min}$. Dry nitrogen gas was used to purge the DSC equipment during measurements at a flow rate of 50 ml/min.

[0021] The mass loss due to solvent or water loss from the crystals was determined by thermo gravimetric analysis (= TGA). During heating of a sample in a TGA/SDTA851e (Mettler-Toledo GmbH, Switzerland) the weight of the sample was monitored resulting in a weight vs. temperature curve. The TGA/SDTA851e was calibrated for temperature with indium and aluminium. Samples were weighed in 100 μl corundum crucibles and heated in the TGA from 25 to 300 $^\circ\text{C}$ with a heating rate of 20 $^\circ\text{C}/\text{min}$. Dry nitrogen gas was used for purging.

[0022] The results of the characterization of the new salt forms of the compound of formula (I) are shown below in Table 2. In this table, reference is made to Tables 3.1 to 3.20, which shows the single crystal data of the salt forms, and to Figures I - 4.1 to LVIII - 4.28 and Tables I - 4.1 to LVIII - 4.28, which shows the X-ray Powder Diffraction (XRPD) diagram and the X-ray powder reflections and intensities of the crystalline salt forms in accordance with the present invention.

Table 2: Thermal analysis, stoichiometry and single crystal data of the different salts of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone

salt form abbreviation	salt form full name	stoichiometry (base:counter-ion)	thermal analysis (T_{fus} & LOD*)	single crystal data	XRPD data
Bas1	free base (= hydrated form)	not relevant	$T_{fus} = 253^\circ\text{C}$ LOD = 1.5 %	see Tab. 3.1	
HCl1	chloride, form I (= anhydrous form)	1:1	$T_{fus} = 275^\circ\text{C}$ LOD = 0.2 %		see Fig. I - 4.1a & Tab. I - 4.1a
HCl2	chloride, form II (= hydrated form)	1:1	$T_{fus} = 275^\circ\text{C}$ LOD = 8.9 %		see Fig. II - 4.1b &

salt form abbreviation	salt form full name	stoichiometry (base:counter-ion)	thermal analysis (T_{fus} & LOD*)	single crystal data	XRPD data
					Tab. II - 4.1b
HBr2	bromide, form II (= hydrated form)	1:1	n.d.	see Tab 3.2	
HBr7	bromide, form VII (= anhydrous form)	1:1	$T_{fus} = 250\text{ }^{\circ}\text{C}$ LOD = 0.7 %		see Fig. III - 4.2a & Tab. III - 4.2 ^a
HBr8	bromide, form VIII	1:1	$T_{fus} = 260\text{ }^{\circ}\text{C}$ LOD = n.d.		see Fig. IV - 4.2b & Tab. IV - 4.2b
Pho1	phosphate, form I	1:1	$T_{fus} = 270\text{ }^{\circ}\text{C}$ LOD: n.d.		see Fig. V - 4.3 & Tab. V - 4.3
Pho2	phosphate, form II (= hydrated form)	1:1	$T_{fus} = 270\text{ }^{\circ}\text{C}$ LOD = 8.5 %	see Tab 3.3	
Sul1	sulfate, form I (= hydrated form)	1:1	$T_{fus} = 270\text{ }^{\circ}\text{C}$ LOD = 5.5 %		see Fig. VI - 4.4a & Tab. VI - 4.4a
Sul5	sulfate, form V	1:1	n.d.		see Fig. VII - 4.4b & Tab. VII - 4.4b
Sul6	sulfate, form VI (= hydrated form)	2:1	$T_{fus} = 245\text{ }^{\circ}\text{C}$ LOD = 6.6 %		see Fig. VIII - 4.4c & Tab. VIII - 4.4c
Sul7	sulfate, form VII (= hydrated form)	2:1	$T_{fus} = 240\text{ }^{\circ}\text{C}$ LOD = n.d.		see Fig. IX - 4.4d & Tab. IX - 4.4d
Mes1	mesylate, form I (= hydrated form)	1:1	$T_{fus} = 255\text{ }^{\circ}\text{C}$ LOD = 1.5 %	see Tab. 3.4	
Eds1	edisylate, form I	1:1 or 2:1	n.d.		see Fig. X - 4.5a &

salt form abbreviation	salt form full name	stoichiometry (base:counter-ion)	thermal analysis (T_{fus} & LOD*)	single crystal data	XRPD data
					Tab. X - 4.5a
Eds2	edisylate, form II	1:1 or 2:1	n.d.		see Fig. XI - 4.5b & Tab. XI - 4.5b
Eds3	edisylate, form III (= hydrated form)	1:1 or 2:1	T_{fus} : n.d. LOD = 4.90 %		
Eds5	edisylate, form V	1:1 or 2:1	n.d.		see Fig. XII - 4.5c & Tab. XII - 4.5c
Eds6	edisylate, form VI	1:1 or 2:1	T_{fus} : ca. 300 °C LOD < 0.5 %		see Fig. XIII - 4.5d & Tab. XIII - 4.5d
Ise1	isethionate, form I (= anhydrous form)	1:1	T_{fus} = 285 °C LOD = 0.3 %	see Tab. 3.5	
Ise2	isethionate, form II	1:1	n.d.		see Fig. XIV - 4.6a & Tab. XIV - 4.6a
Ise4	isethionate, form IV	1:1	n.d.		See Fig. XV - 4.6b & Tab. XV - 4.6b
Ise5	isethionate, form V (= hydrated form)	1:1	n.d.	see Tab 3.6	
Bes1	besylate, form I (= hydrated form)	1:1	n.d.	see Tab. 3.7	
Bes3	besylate, form III (= anhydrous form)	1:1	T_{fus} = 258 °C LOD < 0.5 %		see Fig. XVI - 4.7a & Tab. XVI - 4.7a
Bes5	besylate, form V (= anhydrous form)	1:1	T_{fus} = 237 °C LOD < 0.5 %		see Fig. XVII - 4.7b & Tab. XVII

salt form abbreviation	salt form full name	stoichiometry (base:counter-ion)	thermal analysis (T_{fus} * & LOD*)	single crystal data	XRPD data
					- 4.7b
Tos1	tosylate, form I (= hydrated form)	1:1	$T_{fus} = 250\text{ }^{\circ}\text{C}$ LOD = 1.5 %	see Tab. 3.8	
Tos2	tosylate, form II (= hydrated form)	1:1	n.d.	see Tab. 3.9	
Cas2	camphorsulfonate, form II (= anhydrous form)	1:1	$T_{fus} = 265\text{ }^{\circ}\text{C}$ LOD < 0.5 %		see Fig. XVIII - 4.8 & Tab. XVIII - 4.8
Cas3	camphorsulfonate, form III (= anhydrous form)	1:1	n.d.	see Tab. 3.10	
Cas5	camphorsulfonate, form V (= solvate)	1:1	$T_{fus} = 268$ LOD = n.d.	see Tab. 3.11	
Cas12	camphorsulfonate, form XII (= solvate)	1:1	n.d.	see Tab. 3.12	
Nds3	naphthalene-1,5- disulfonate, form III	1:1	$T_{fus} = 93\text{ }^{\circ}\text{C}$ LOD = n.d.		see Fig. XIX - 4.9a & Tab. XIX - 4.9a
Nds5	naphthalene-1,5- disulfonate, form V (= hydrated form)	1:1	T_{fus} : ca. $150\text{ }^{\circ}\text{C}$ LOD = 2.0 %		See Fig. XX - 4.9b & Tab. XX - 4.9b
Cit1	citrate, form I (= anhydrous form)	1:1 or 2:1	$T_{fus} = 200\text{ }^{\circ}\text{C}$ LOD = 0.2 %		see Fig. XXI - 4.10 & Tab. XXI - 4.10
Cit2	citrate, form II (= hydrated form)	2:1	$T_{fus} = 220\text{ }^{\circ}\text{C}$ LOD = 3.0 %	see Tab. 3.13	
D-Tar1	D-tartrate, form I (= hydrated form)	1:1	$T_{fus} = 240\text{ }^{\circ}\text{C}$ LOD = 3.1 %		see Fig. XXII - 4.11a & Tab. XXII - 4.11a
L-Tar1	L-tartrate, form I (= hydrated form)	1:1	$T_{fus} = 240\text{ }^{\circ}\text{C}$ LOD = 3.1 %		see Fig. XXIII -

salt form abbreviation	salt form full name	stoichiometry (base:counter-ion)	thermal analysis (T_{fus} & LOD*)	single crystal data	XRPD data
					4.12a & Tab. XXIII - 4.12a
D-Tar2	D-tartrate, form II	2:1	$T_{fus} = 244\text{ }^{\circ}\text{C}$ LOD = 4.2 %		see Fig. XXIV - 4.11b & Tab. XXIV - 4.11b
L-Tar2	L-tartrate, form II	2:1	$T_{fus} = 245\text{ }^{\circ}\text{C}$ LOD = 4.0 %		see Fig. XXV - 4.12b & Tab. XXV - 4.12b
Fum1	fumarate, form I (= hydrated form)	2:1	$T_{fus} = 265\text{ }^{\circ}\text{C}$ LOD = 7.9 %		see Fig. XXVI - 4.13a & Tab. XXVI - 4.13a
Fum3	fumarate, form III (= anhydrous form)	2:1	$T_{fus} = 263\text{ }^{\circ}\text{C}$ LOD < 0.5 %		see Fig. XXVII - 4.13b & Tab. XXVII - 4.13b
Mae1	maleate, form I (= anhydrous form)	2:1	$T_{fus} = 225\text{ }^{\circ}\text{C}$ LOD = 0.6 %		see Fig. XXVIII - 4.14 & Tab. XXVIII - 4.14
L-Lac1	L-lactate, form I (= hydrated form)	1:1	$T_{fus} = 220\text{ }^{\circ}\text{C}$ LOD = 6.7 %	see Tab. 3.14	
Glc1	glycolate, form I (= hydrated form)	1:1	$T_{fus} = 230\text{ }^{\circ}\text{C}$ LOD = 6.9 %		see Fig. XXIX - 4.15 & Tab. XXIX - 4.15
Gly1	glycinate, form I	1:1	n.d.		see Fig. XXX - 4.16 & Tab. XXX - 4.16
L-Mal1	L-malate, form I (= hydrated form)	1:1	$T_{fus} = 215\text{ }^{\circ}\text{C}$ LOD = 2.5 %		see Fig. XXXI - 4.17a &

salt form abbreviation	salt form full name	stoichiometry (base:counter-ion)	thermal analysis (T_{fus} & LOD ^a)	single crystal data	XRPD data
					Tab. XXXI - 4.17a
D-Mal1	D-malate, form I (= hydrated form)	1:1	$T_{fus} = 215\text{ }^{\circ}\text{C}$ LOD = 2.5 %		see Fig. XXXII - 4.18a & Tab. XXXII - 4.18a
L-Mal2	L-malate, form II	1:1 or 2:1	n.d.		see Fig. XXXIII - 4.17b & Tab. XXXIII - 4.17b
L-Mal3	L-malate, form III	2:1	$T_{fus} = 220\text{ }^{\circ}\text{C}$ LOD: n.d.	see Tab. 3.15	
D-Mal3	D-malate, form III	2:1	$T_{fus} = 220\text{ }^{\circ}\text{C}$ LOD: n.d.		see Fig. XXXIV - 4.18b & Tab. XXXIV - 4.18b
Mao1	malonate, form I (= hydrated form)	1:1 or 2:1	T_{fus} : ca. $185\text{ }^{\circ}\text{C}$ LOD = 4.3 %		see Fig. XXXV - 4.19a & Tab. XXXV - 4.19a
Mao2	malonate, form II (= hydrated form)	1:1 or 2:1	T_{fus} : ca. $185\text{ }^{\circ}\text{C}$ LOD = 7.4 %		see Fig. XXXVI - 4.19b & Tab. XXXVI - 4.19b
Mao3	malonate, form III (= hydrated and/or solvated form)	2:1	$T_{fus} = 251\text{ }^{\circ}\text{C}$ LOD = 13.7 %		see Fig. XXXVII - 4.19c & Tab. XXXVII - 4.19c
Mao4	malonate, form IV	2:1	$T_{fus} = 252\text{ }^{\circ}\text{C}$ LOD: n.d.		see Fig. XXXVIII - 4.19d & Tab. XXXVIII -

salt form abbreviation	salt form full name	stoichiometry (base:counter-ion)	thermal analysis (T_{fus} & LOD*)	single crystal data	XRPD data
					4.19d
Mao6	malonate, form VI	2:1	$T_{fus} = 252\text{ }^{\circ}\text{C}$ LOD: n.d.		see Fig. XXXIX - 4.19e & Tab. XXXIX - 4.19e
Suc1	succinate, form I (= hydrated form)	2:1	$T_{fus} = 139\text{ }^{\circ}\text{C}$ LOD = 1.2 %		see Fig. XL - 4.20a & Tab. XL - 4.20a
Suc2	succinate, form II (= hydrated form)	2:1	T_{fus} : ca. $220\text{ }^{\circ}\text{C}$ LOD = 2.0 %		see Fig. XLI - 4.20b & Tab. XLI - 4.20b
Suc3	succinate, form III (= hydrated form)	2:1	T_{fus} : ca. $210\text{ }^{\circ}\text{C}$ LOD = 8.4 %	see Tab. 3.16	
Oxa3	oxalate, form III (= hydrated form)	1:1 or 2:1	$T_{fus} = 245\text{ }^{\circ}\text{C}$ LOD = 5.7 %		see Fig. XLII - 4.21a & Tab. XLII - 4.21a
Oxa5	oxalate, form V	1:1 or 2:1	n.d.		see Fig. XLIII - 4.21b & Tab. XLIII - 4.21b
Oxa6	oxalate, form VI (= hydrated form)	2:1	$T_{fus} = 244\text{ }^{\circ}\text{C}$ LOD = 7.0 %		see Fig. XLIV - 4.21c & Tab. XLIV - 4.21c
Gen1	2,5- dihydroxybenzoate form I (= hydr. form)	1:1	T_{fus} : ca. $225\text{ }^{\circ}\text{C}$ LOD = 2.3 %		see Fig. XLV - 4.22 & Tab. XLV - 4.22
Gen11	2,5- dihydroxybenzoate form XI (= hydr. form)	1:1	n.d.	see Tab. 3.17	
Cam2	camphorate, form II (= hydrated form)	1:1	T_{fus} : n.d. LOD: 1.9 %.		see Fig. XLVI -

salt form abbreviation	salt form full name	stoichiometry (base:counter-ion)	thermal analysis (T_{fus} & LOD [*])	single crystal data	XRPD data
					4.23a & Tab. XLVI - 4.23a
Cam3	camphorate, form III	1:1	T_{fus} : n.d. LOD: 0.5 %		see Fig. XLVII - 4.23b & Tab. XLVII - 4.23b
Ben2	benzoate, form II (= hydrated form)	1:1	T_{fus} = 175 °C LOD = 6.0 %		see Fig. XLVIII - 4.24a & Tab. XLVIII - 4.24a
Ben3	benzoate, form III	1:1	n.d.		see Fig. XLIX - 4.24b & Tab. XLIX - 4.24b
Man1	mandelate, form I (= hydrated form)	1:1	T_{fus} = 255 °C LOD = 2.6	see Tab. 3.18	
Sac3	saccharinate, form III	1:1	n.d.		see Fig. L - 4.25a & Tab. L - 4.25a
Sac5	saccharinate, form V (= hydrated form)	1:1	T_{fus} = 180 °C LOD = 2.8 %		see Fig. LI - 4.25b & Tab. LI - 4.25b
Sal1	salicylate, form I	1:1	T_{fus} = 248 °C LOD: n.d.		see Fig. LII - 4.26 & Tab. LII - 4.26
Sal2	salicylate, form II (= anhydrous form)	1:1	T_{fus} = 245 °C LOD: n.d.	see Tab. 3.19	
L-Asp1	L-aspartate, form I (= hydrated form)	2:1	T_{fus} = 245 °C LOD = 6.8 %		see Fig. LIII - 4.27a & Tab. LIII - 4.27a

salt form abbreviation	salt form full name	stoichiometry (base:counter-ion)	thermal analysis (T_{fus} * & LOD*)	single crystal data	XRPD data
L-Asp2	L-aspartate, form II	2:1	n.d.		see Fig. LIV - 4.27b & Tab. LIV - 4.27b
Xin1	xinafoate, form I (= hydrated form)	1:1	$T_{\text{fus}} = 164\text{ }^{\circ}\text{C}$ LOD = 2.8 %	see Tab. 3.20	
Asc1	ascorbate, form I	1:1	$T_{\text{fus}} = 247\text{ }^{\circ}\text{C}$ LOD = n.d.		see Fig. LV - 4.28a & Tab. LV - 4.28a
Asc3	ascorbate, form III	1:1	$T_{\text{fus}} = 234\text{ }^{\circ}\text{C}$ LOD = n.d.		see Fig. LVI - 4.28b & Tab. LVI - 4.28b
Asc4	ascorbate, form IV	1:1	$T_{\text{fus}} = 236\text{ }^{\circ}\text{C}$ LOD = n.d.		see Fig. LVII - 4.28c & Tab. LVII - 4.28c

* T_{fus} = melting point

*LOD = loss on drying up to the melting point

n.d. = not determined

Table 3.1 Single crystal data and structure refinement of Bas1 = free base (= hemihydrate)

Empirical formula	$\text{C}_{31}\text{H}_{34}\text{N}_5\text{O}_4 \cdot 0.5 \text{H}_2\text{O}$
Fw	549.64
T [K]	293(2) K
λ [Å]	0.71073 Å
Crystal system	Triclinic
Space group	P -1
Unit cell dimensions	

EP 2 364 968 A1

(continued)

Empirical formula	$C_{31}H_{34}N_5O_4 \cdot 0.5 H_2O$
a [Å]	10.5430(3)
b [Å]	10.9130(4)
c [Å]	13.8380(6)
α [°]	78.147 (2)
β [°]	89.713(3)
γ [°]	67.834(4)
V [Å ³]	1438.41(9)
Z	2
D _m [g/cm ³]	1.269
F(000)	584
Crystal size [mm ³]	0.2 x 0.15 x 0.15
θ range [°]	2.50 → 27.3°
Reflections collected	9836
Independent reflections	6343 [R_{int}] = 0.0430]
S	1.043
R [$I > 2\sigma(I)$]	R1 = 0.0796, wR2 = 0.1621
R indices (all data)	R1 = 0.1761, wR2 = 0.2009
Extinction coefficient	0.044(4)
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D _m = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F ² ; R [$I > 2\sigma(I)$] = Final R indices [$I > 2\sigma(I)$]	

Table 3.2 Single crystal data and structure refinement of HBr2 = bromide, Form II (trihydrate)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot Br^- \cdot 3 H_2O$
Fw	674.59
T [K]	293(2)
λ [Å]	0.71073
Crystal system	Triclinic
Space group	P-1
Unit cell dimensions	
a [Å]	9.2250(2)
b [Å]	12.4280(2)
c [Å]	15.4280(3)
α [°]	103.8360(7)
β [°]	101.4230(8)
γ [°]	96.1460(7)
V [Å ³]	1661.14(5)

EP 2 364 968 A1

(continued)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot Br^- \cdot 3 H_2O$
Z	2
D_m [g/cm ³]	1.349
F(000)	704
Crystal size [mm ³]	0.2 x 0.2 x 0.2
θ range [°]	3.00 → 27.5
Reflections collected	12767
Independent reflections	7487 [$R_{int} = 0.0250$]
S	1.041
R [$I > 2\sigma(I)$]	$R1 = 0.0452$, $wR2 = 0.0947$
R indices (all data)	$R1 = 0.0703$, $wR2 = 0.1076$
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D_m = calculated density; θ range = Theta range of data collection; S = Goodness-of-fit on F^2 ; R [$I > 2\sigma(I)$] = Final R indices [$I > 2\sigma(I)$]	

Table 3.3 Single crystal data and structure refinement of Pho2 = phosphate, Form II (3,5 - hydrate)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot H_2PO_4^- \cdot 3.5 H_2O$
Fw	700.67
T [K]	293(2)
λ [Å]	0.71073
Crystal system	Monoclinic
Space group	P 2 ₁ /c
Unit cell dimensions	
a [Å]	17.1960(3)
b [Å]	11.8290(2)
c [Å]	37.7530(6)
β [°]	116.007(2)
V [Å ³]	6901.8(2)
Z	8
D_m [g/cm ³]	1.349
F(000)	2968
Crystal size [mm ³]	0.2 x 0.2 x 0.1
θ range [°]	1.3 → 22.5
Reflections collected	16435
Independent reflections	9001 [$R_{int} = 0.0518$]
S	1.081
R [$I > 2\sigma(I)$]	$R1 = 0.0860$, $wR2 = 0.2095$

EP 2 364 968 A1

(continued)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot H_2PO_4^- \cdot 3.5 H_2O$
R indices (all data)	R1 = 0.1217, wR2 = 0.2314
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D_m = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F^2 ; R [$I > 2\sigma(I)$] = Final R indices [$I > 2\sigma(I)$]	

Table 3.4 Single crystal data and structure refinement of Mes1 = mesylate, Form I (= hemihydrate)

Empirical formula	$C_{32}H_{34}N_5O_4^+ \cdot CH_3SO_3^- \cdot 0.5 H_2O$
Fw	644.73
T [K]	293(2)
λ [Å]	0.71073
Crystal system	Triclinic
Space group	P-1
Unit cell dimensions	
a [Å]	11.3700(6)
b [Å]	16.4940(6)
c [Å]	19.0370(8)
α [°]	68.124(3)
β [°]	84.892(2)
γ [°]	89.884(2)
V [Å ³]	3298.0(3)
Z	4
D_m [g/cm ³]	1.298
F(000)	1364
Crystal size [mm ³]	0.15 x 0.12 x 0.1
θ range [°]	2→24
Reflections collected	11140
Independent reflections	8267 [$R_{int} = 0.0541$]
S	1.080
R [$I > 2\sigma(I)$]	R1 = 0.0746, wR2 = 0.1635
R indices (all data)	R1 = 0.1210, wR2 = 0.1889
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D_m = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F^2 ; R [$I > 2\sigma(I)$] = Final R indices [$I > 2\sigma(I)$]	

Table 3.5 Single crystal data and structure refinement of Ise1 = isethionate, Form I (= anhydrous form)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot C_2H_6SO_4^-$
Fw	665.75

EP 2 364 968 A1

(continued)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot C_2H_6SO_4^-$
T [K]	293(2)
λ [Å]	0.71073
Crystal system	Monoclinic
Space group	P 2 ₁ /c
Unit cell dimensions	
a [Å]	18.2760(4)
b [Å]	10.3290(7)
c [Å]	19.1750(8)
β [°]	112.934(2)
V [Å ³]	3333.6(3)
Z	4
D _m [g/cm ³]	1.327
Absorption coefficient	0.155
F(000)	1408
Crystal size [mm ³]	0.2 x 0.15 x 0.05
θ range [°]	2.25 → 24.25
Reflections collected	13587
Independent reflections	5148 [R(int) = 0.1346]
Goodness-of-fit on F ²	1.110
R [$I > 2\sigma(I)$]	R1 = 0.1014, wR2 = 0.1324
R indices (all data)	R1 = 0.2081, wR2 = 0.1566
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D _m = calculated density; θ range = Theta range of data collection; S = Goodness-of-fit on F ² ; R [$I > 2\sigma(I)$] = Final R indices [$I > 2\sigma(I)$]	

Table 3.6 Crystal data and structure refinement of lse5 = isethionate, Form V (= dihydrate)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot C_2H_6SO_4^-$
Fw	665.75
T [K]	293(2)
λ [Å]	0.71073
Crystal system	Monoclinic
Space group	P 2 ₁ /c
Unit cell dimensions	
a [Å]	18.2760(4)
b [Å]	10.3290(7)
c [Å]	19.1750(8)
β [°]	112.934(2)

EP 2 364 968 A1

(continued)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot C_2H_6SO_4^-$
V [$\text{\AA}^3$]	3333.6(3)
Z	4
D ₃ [g/cm ³]	1.327
Absorption coefficient	0.155
F(000)	1408
Crystal size [mm ³]	0.2 x 0.15 x 0.05
θ range [°]	2.25 → 24.25
Reflections collected	13587
Independent reflections	5148 [R(int) = 0.1346]
S	1.110
R [$I > 2\sigma(I)$]	R1 = 0.1014, wR2 = 0.1324
R indices (all data)	R1 = 0.2081, wR2 = 0.1566
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D _m = calculated density; θ range = Theta range of data collection; S = Goodness-of-fit on F ² ; R [$I > 2\sigma(I)$] = Final R indices [$I > 2\sigma(I)$]	

Table 3.7 Crystal data and structure refinement of Bes1 = besylate, Form I (= trihydrate)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot C_6H_5SO_3^- \cdot 3 H_2O$
Fw	751.84
T [K]	293(2)
λ [$\text{\AA}$]	0.71073
Crystal system	Triclinic
Space group	P-1
Unit cell dimensions	
a [$\text{\AA}$]	9.2700(2)
b [$\text{\AA}$]	11.8820(3)
c [$\text{\AA}$]	17.3410(5)
α [°]	86.4650(11)
β [°]	89.0940(11)
γ [°]	81.3340(17)
V [$\text{\AA}^3$]	1884.60(8)
Z	2
D _m [g/cm ³]	1.325
F(000)	796
Crystal size [mm ³]	0.6 x 0.2 x 0.1
θ range [°]	2 → 25
Reflections collected	11462

EP 2 364 968 A1

(continued)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot C_6H_5SO_3^- \cdot 3 H_2O$
Independent reflections	6607 [$R_{int} = 0.0267$]
S	1.025
R [$I > 2\sigma(I)$]	$R1 = 0.0565$, $wR2 = 0.1401$
R indices (all data)	$R1 = 0.0794$, $wR2 = 0.1543$
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D_m = calculated density; θ range = Theta range of data collection; S = Goodness-of-fit on F^2 ; R [$I > 2\sigma(I)$] = Final R indices [$I > 2\sigma(I)$]	

Table 3.8 Crystal data and structure refinement of Tos1 = tosylate, Form I (= monohydrate)

Empirical formula	$C_{38}H_{34}N_5O_4^+ \cdot C_7H_7O_3S^- \cdot H_2O$
Fw	729.83
T [K]	293(2)
λ [Å]	0.71073
Crystal system	Triclinic
Space group	P-1
Unit cell dimensions	
a [Å]	10.0670(8)
b [Å]	11.5880(9)
c [Å]	17.4860(19)
α [°]	85.599(4)
β [°]	88.670(5)
γ [°]	68.083(9)
V [Å ³]	1886.8(3)
Z	2
D_m [g/cm ³]	1.285
F(000)	772
Crystal size [mm ³]	0.15 x 0.1 x 0.01
θ range [°]	2→23.
Reflections collected	4871
Independent reflections	3713 [$R_{int} = 0.0789$]
S	1.065
R [$I > 2\sigma(I)$]	$R1 = 0.1187$, $wR2 = 0.2008$
R indices (all data)	$R1 = 0.2506$, $wR2 = 0.2529$
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D_m = calculated density; θ range = Theta range of data collection; S = Goodness-of-fit on F^2 ; R [$I > 2\sigma(I)$] = Final R indices [$I > 2\sigma(I)$]	

Table 3.9 Crystal data and structure refinement of Tos2 = tosylate, Form II (= trihydrate)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot C_6H_5O_3S^- \cdot 3H_2O$
Fw	765.87
T [K]	293(2)
λ [Å]	0.71073
Crystal system	Triclinic
Space group	P-1
Unit cell dimensions	
a [Å]	9.2760(2)
b [Å]	12.4080(2)
c [Å]	17.1470(4)
α [°]	87.634(1)
β [°]	89.104(1)
γ [°]	78.453(2)
V [Å ³]	1931.92(7) Å
Z	2
D _m [g/cm ³]	1.317
F(000)	812
Crystal size [mm ³]	0.2 x 0.15 x 0.1
θ range [°]	2.2 → 27.5
Reflections collected	13198
Independent reflections	8761 [R_{int}] = 0.0238]
S	1.019
R [$I > 2\sigma(I)$]	R1 = 0.0560, wR2 = 0.1301
R indices (all data)	R1 = 0.0831, wR2 = 0.1448
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D _m = calculated density; θ range = Theta range of data collection; S = Goodness-of-fit on F ² ; R [$I > 2\sigma(I)$] = Final R indices [$I > 2\sigma(I)$]	

Table 3.10 Crystal data and structure refinement of Cas3 = camphorsulfonate, Form III (= anhydrous form)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot C_{10}H_{15}SO_4^-$
Fw	771.91
T [K]	293(2)
λ [Å]	0.71073
Crystal system	Triclinic
Space group	P-1
Unit cell dimensions	
a [Å]	9.7410(3)
b [Å]	12.5540(4)

EP 2 364 968 A1

(continued)

	Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot C_{10}H_{15}SO_4^-$
5	c [Å]	17.6910(6)
	α [°]	73.3620(12)
	β [°]	75.9590(12)
	γ [°]	80.0360(17)
10	V [Å ³]	1998.38(11)
	Z	2
	D _m [g/cm ³]	1.283
15	F(000)	820
	Crystal size [mm ³]	0.25 x 0.2 x 0.15
	θ range [°]	2.6 → 24.5.
	Reflections collected	11336
20	Independent reflections	6629 [R _{int} = 0.0423]
	S	1.106
	R [$I > 2\sigma(I)$]	R1 = 0.0701, wR2 = 0.1452
25	R indices (all data)	R1 = 0.1073, wR2 = 0.1585
	Extinction coefficient	0.0231(13)
30	Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D _m = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F ² ; R [$I > 2\sigma(I)$] = Final R indices [$I > 2\sigma(I)$]	

Table 3.11 Crystal data and structure refinement of Cas5 = camphorsulfonate, Form V (= hemisolvate with propionitrile)

35	Empirical formula	$C_{31}H_{34}N_5O_4 \cdot C_{10}H_{15}O_4S^- \cdot 0.5 C_3H_5N$
	Fw	799.45
	T [K]	293(2)
40	λ [Å]	0.71073
	Crystal system	Triclinic
	Space group	P1
45	Unit cell dimensions	
	a [Å]	9.5050(5)
	b [Å]	13.1300(7)
	c [Å]	17.903(2)
50	α [°]	78.389(2)
	β [°]	76.262(2)
	γ [°]	89.425(4)
55	V [Å ³]	2124.3(2)
	Z	2
	D _m [g/cm ³]	1.250

EP 2 364 968 A1

(continued)

Empirical formula	$C_{31}H_{34}N_5O_4 \cdot C_{10}H_{15}O_4S^- \cdot 0.5 C_3H_5N$
F(000)	850
Crystal size [mm ³]	0.4 x 0.2 x 0.2
θ range [°]	2.2 → 25.5
Reflections collected	11323
Independent reflections	11323 [$R_{int} = 0.0000$]
S	1.067
R [$I > 2\sigma(I)$]	$R_1 = 0.0603$, $wR_2 = 0.1672$
R indices (all data)	$R_1 = 0.0681$, $wR_2 = 0.1772$
Absolute structure parameter	0.03(9)
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D_m = calculated density; θ range = Theta range of data collection; S = Goodness-of-fit on F^2 ; R [$I > 2\sigma(I)$] = Final R indices [$I > 2\sigma(I)$]	

Table 3.12 Crystal data and structure refinement of Cas12 = camphorsulfonate, Form XII (= hemisolvate with 1,2-dimethoxyethane)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot C_{10}H_{15}O_4S^- \cdot 0.5 C_4H_{10}O_2$
Fw	816.97
T [K]	293(2)
λ [Å]	0.71073
Crystal system	Triclinic
Space group	P1
Unit cell dimensions	
a [Å]	10.854(1)
b [Å]	11.289(1)
c [Å]	18.421(2)
α [°]	105.02(1)
β [°]	96.38(1)
γ [°]	104.27(1)
V [Å ³]	2075.5(2)
Z	2
D_m [g/cm ³]	1.307
F(000)	870
Crystal size [mm ³]	0.3 x 0.2 x 0.15
θ range [°]	3 → 26
Reflections collected	7261
Independent reflections	7261 [$R_{int} = 0.0000$]
S	1.058
R [$I > 2\sigma(I)$]	$R_1 = 0.0680$, $wR_2 = 0.1378$

EP 2 364 968 A1

(continued)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot C_{10}H_{15}O_4S^- \cdot 0.5 C_4H_{10}O_2$
R indices (all data)	R1 = 0.1069, wR2 = 0.1550
Absolute structure parameter	-0.12(13)
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D_m = calculated density; θ range = Theta range of data collection; S = Goodness-of-fit on F^2 ; R [$I > 2\sigma(I)$] = Final R indices [$I > 2\sigma(I)$]	

Table 3.13 Crystal data and structure refinement of Cit2 = citrate, Form II (= dihydrate)

Empirical formula	$2 (C_{31}H_{34}N_5O_4^+) \cdot C_6H_6O_7^{2-} \cdot 2 H_2O$
Fw	1307.4
T [K]	293(2) K
λ [Å]	0.71073 Å
Crystal system	Triclinic
Space group	P-1
Unit cell dimensions	
a [Å]	12.2450(3)
b [Å]	15.4250(4)
c [Å]	18.6640(6)
α [°]	77.523(1)
β [°]	78.303(1)
γ [°]	88.705(2)
V [Å ³]	3369.68(16)
Z	2
D_m [g/cm ³]	1.289
F(000)	1384
Crystal size [mm ³]	0.25 x 0.18 x 0.1
θ range [°]	2 → 22.5
Reflections collected	14407
Independent reflections	8753 [$R_{int} = 0.0320$]
S	1.047
R [$I > 2\sigma(I)$]	R1 = 0.0859, wR2 = 0.2323
R indices (all data)	R1 = 0.1163, wR2 = 0.2611
Extinction coefficient	0.020(3)
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D_m = calculated density; θ range = Theta range of data collection; S = Goodness-of-fit on F^2 ; R [$I > 2\sigma(I)$] = Final R indices [$I > 2\sigma(I)$]	

Table 3.14 Crystal data and structure refinement of L-Lac1 = L-lactate, Form I (= 2.5 - hydrate)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot C_3H_4O_3^- \cdot 2.5 H_2O$
Fw	674.74
T [K]	293(2)
λ [Å]	0.71073
Crystal system	Monoclinic
Space group	P 2 ₁
Unit cell dimensions	
a [Å]	16.8380(6)
b [Å]	11.7710(9)
c [Å]	17.3490(12)
β [°]	91.819(3)
V [Å ³]	3436.8(4)
Z	4
D _m [g/cm ³]	1.304
F(000)	1436
Crystal size [mm ³]	0.15 x 0.1 x 0.05
θ range [°]	2.5 → 26.00
Reflections collected	14324
Independent reflections	10572 [R_{int} = 0.0709]
S	1.042
R [$I > 2\sigma(I)$]	R1 = 0.0881, wR2 = 0.1583
R indices (all data)	R1 = 0.1950, wR2 = 0.1977
Absolute structure parameter	0.8(19)
Extinction coefficient	0.0110(11)
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D _m = calculated density; θ range = Theta range of data collection; S = Goodness-of-fit on F ² ; R [$I > 2\sigma(I)$] = Final R indices [$I > 2\sigma(I)$]	

Table 3.15 Crystal data and structure refinement of L-Mal3 = L-malate, Form III (= tetrahydrate)

Empirical formula	$2 (C_{31}H_{34}N_5O_4^+) \cdot C_4H_4O_5^{2-} \cdot 4 H_2O$
Fw	1285.40
T [K]	293(2)
λ [Å]	0.71073
Crystal system	Triclinic
Space group	P1
Unit cell dimensions	
a [Å]	9.2360(3)
b [Å]	11.1340(4)

EP 2 364 968 A1

(continued)

Empirical formula	$2 (\text{C}_{31}\text{H}_{34}\text{N}_5\text{O}_4^+) \cdot \text{C}_4\text{H}_4\text{O}_5^{2-} \cdot 4 \text{H}_2\text{O}$
c [Å]	16.5470(6)
α [°]	86.3520(19)
β [°]	74.7070(19)
γ [°]	84.372(2)
V [Å ³]	1632.16(10)
Z	1
D _m [g/cm ³]	1.308
F(000)	682
Crystal size [mm ³]	0.15 x 0.1 x 0.06
θ range [°]	3 → 22.50
Reflections collected	7968
Independent reflections	7968 [R _{int} = 0.0000]
S	1.064
R [I > 2σ(I)]	R1 = 0.0711, wR2 = 0.1242
R indices (all data)	R1 = 0.1215, wR2 = 0.1458
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D _m = calculated density; θ range = Theta range of data collection; S = Goodness-of-fit on F ² ; R [I > 2σ(I)] = Final R indices [I > 2σ(I)]	

Table 3.16 Crystal data and structure refinement of Suc3 = succinate, Form III (= hexahydrate)

Empirical formula	$2(\text{C}_{31}\text{H}_{34}\text{N}_5\text{O}_4^+) \bullet \text{C}_4\text{H}_4\text{O}_4^{2-} \bullet 6\text{H}_2\text{O}$
Fw	1305.44
T [K]	293(2)
λ [Å]	0.71073
Crystal system	Triclinic
Space group	P—1
Unit cell dimensions	
a [Å]	8.9690(4)
b [Å]	12.0910(6)
c [Å]	17.037(2)
α [°]	95.004(3)
β [°]	103.678(3)
γ [°]	109.813(5)
V [Å ³]	1660.35(15)
Z	1
D _m [g/cm ³]	1.306
F(000)	694

EP 2 364 968 A1

(continued)

Empirical formula	$2(\text{C}_{31}\text{H}_{34}\text{N}_5\text{O}_4^+) \bullet \text{C}_4\text{H}_4\text{O}_4^{2-} \bullet 6\text{H}_2\text{O}$
Crystal size [mm^3]	$0.3 \times 0.15 \times 0.05$
θ range [$^\circ$]	$3.5 \rightarrow 27.4$
Reflections collected	6180
Independent reflections	4915 [$R(\text{int}) = 0.0418$]
S	1.024
R [$I > 2\sigma(I)$]	$R1 = 0.0747$, $wR2 = 0.1213$
R indices (all data)	$R1 = 0.1662$, $wR2 = 0.1478$
Extinction coefficient	0.035(3)
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D_m = calculated density; θ range = Theta range of data collection; S = Goodness-of-fit on F^2 ; $R [I > 2\sigma(I)]$ = Final R indices [$I > 2\sigma(I)$]	

Table 3.17 Crystal data and structure refinement of Gen11 = gentisate, Form XI (= hemihydrate)

Empirical formula	$\text{C}_{31}\text{H}_{34}\text{N}_5\text{O}_4 \cdot \text{C}_7\text{H}_5\text{O}_4 \cdot 0.5 \cdot \text{H}_2\text{O}$
Fw	702.75
T [K]	293(2)
λ [$\text{\AA}$]	0.71073
Crystal system	Triclinic
Space group	P—1
Unit cell dimensions	
a [$\text{\AA}$]	14.919(2)
b [$\text{\AA}$]	15.713(2)
c [$\text{\AA}$]	17.136(2)
α [$^\circ$]	93.770(3)
β [$^\circ$]	113.268(4)
γ [$^\circ$]	104.383(3)
V [$\text{\AA}^3$]	3513.5(5)
Z	4
D_m [g/cm^3]	1.329
F(000)	1484
Crystal size [mm^3]	$0.25 \times 0.25 \times 0.2$
θ range [$^\circ$]	2–25
Reflections collected	19141
Independent reflections	11651 [$R(\text{int}) = 0.0451$]
S	1.203
R [$I > 2\sigma(I)$]	$R1 = 0.1079$, $wR2 = 0.1734$

EP 2 364 968 A1

(continued)

Empirical formula	$C_{31}H_{34}N_5O_4 \cdot C_7H_5O_4 \cdot 0.5 \cdot H_2O$
R indices (all data)	$R1 = 0.1712, wR2 = 0.1958$
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D_m = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F^2 ; R [$I > 2\sigma(I)$] = Final R indices [$I > 2\sigma(I)$]	

Table 3.18 Crystal data and structure refinement of Man1 = mandelate, Form I (= monohydrate)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot C_8H_7O_3^- \cdot H_2O$
Fw	709.78
T [K]	293(2)
λ [Å]	0.71073
Crystal system	Triclinic
Space group	P 1
Unit cell dimensions	
a [Å]	9.9160(3)
b [Å]	11.2690(4)
c [Å]	16.6690(7)
α [°]	89.0210(13)
β [°]	82.4760(13)
γ [°]	76.969(2)
V [Å ³]	1798.91(11)
Z	2
D_m [g/cm ³]	1.310
F(000)	752
Crystal size [mm ³]	0.25 x 0.2 x 0.1
θ range [°]	2.3 → 27.4
Reflections collected	12776
Independent reflections	12776 [$R_{int} = 0.0000$]
S	1.036
R [$I > 2\sigma(I)$]	$R1 = 0.0806, wR2 = 0.1606$
R indices (all data)	$R1 = 0.1481, wR2 = 0.1928$
Absolute structure parameter	-0.5(16)
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D_m = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F^2 ; R [$I > 2\sigma(I)$] = Final R indices [$I > 2\sigma(I)$]	

Table 3.19 Crystal data and structure refinement of Sal2 = salicylate, Form II (= anhydrous form)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot C_7H_5O_3^-$
Fw	677.74
T [K]	293(2)
λ [Å]	0.71073
Crystal system	Triclinic
Space group	P—1
Unit cell dimensions	
a [Å]	9.8770(2)
b [Å]	13.4820(3)
c [Å]	13.6460(3)
α [°]	93.8310(10)
β [°]	99.2880(10)
γ [°]	103.131(2)
V [Å ³]	1736.3(1)
Z	2
D _m [g/cm ³]	1.296
F(000)	716
Crystal size [mm ³]	0.3 × 0.2 × 0.1
θ range [°]	2 → 25
Reflections collected	10009
Independent reflections	6037 [$R_{int} = 0.0233$]
S	1.040
R [$I > 2\sigma(I)$]	$R1 = 0.0543$, $wR2 = 0.1304$
R indices (all data)	$R1 = 0.0713$, $wR2 = 0.1438$
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D _m = calculated density; θ range = Theta range of data collection; S = Goodness-o- fit on F ² ; R [$I > 2\sigma(I)$] = Final R indices [$I > 2\sigma(I)$]	

Table 3.20 Crystal data and structure refinement of Xin1 = xinafoate, Form I (= monohydrate)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot C_{11}H_9O_3^- \cdot H_2O$
Fw	745.81
T [K]	293(2)
λ [Å]	0.71073
Crystal system	Monoclinic
Space group	P 2 ₁ /c
Unit cell dimensions	
a [Å]	11.0350(2)
b [Å]	31.2480(7)

(continued)

Empirical formula	$C_{31}H_{34}N_5O_4^+ \cdot C_{11}H_9O_3^- \cdot H_2O$
c [Å]	11.3790(3)
β [°]	94.298(1)
V [Å ³]	3912.69(15)
Z	4
D _m [g/cm ³]	1.266
F(000)	1576
Crystal size [mm ³]	0.4 × 0.2 × 0.1
θ range [°]	2 → 24.5
Reflections collected	19328
Independent reflections	6429 ($R_{int} = 0.0497$)
S	1.033
R [$I > 2\sigma(I)$]	R1 = 0.0622, wR2 = 0.1307
R indices (all data)	R1 = 0.1066, wR2 = 0.1498
Fw = formula weight; T = Temperature of data collection; λ = wavelength of X-ray source; D _m = calculated density; θ range = Theta range of data collection; S = Goodness-of-fit on F ² ; R [$I > 2\sigma(I)$] = Final R indices [$I > 2\sigma(I)$]	

Brief description of the Figures

[0023]

Figure I - 4.1a: X-ray powder diffraction diagram of HCl1 = chloride, form I (anhydrous)
 Figure II - 4.1b: X-ray powder diffraction diagram of HCl2 = chloride, form II (hydrated form)
 Figure III - 4.2a: X-ray powder diffraction diagram of HBr7 = bromide, form VII (anhydrous form)
 Figure IV - 4.2b: X-ray powder diffraction diagram of HBr8 = bromide, form VIII
 Figure V - 4.3: X-ray powder diffraction diagram of Pho1 = phosphate, form I
 Figure VI - 4.4a: X-ray powder diffraction diagram of Sul1 = sulfate, form I (hydrated form)
 Figure VII - 4.4b: X-ray powder diffraction diagram of Sul5 = sulfate, form V
 Figure VIII - 4.4c: X-ray powder diffraction diagram of Sul6 = sulfate, form VI (hydrated form)
 Figure IX - 4.4d: X-ray powder diffraction diagram of Sul7 = sulfate, form VII
 Figure X - 4.5a: X-ray powder diffraction diagram of Eds1 = edisylate, form I
 Figure XI - 4.5b: X-ray powder diffraction diagram of Eds2 = edisylate, form II
 Figure XII - 4.5c: X-ray powder diffraction diagram of Eds5 = edisylate, form V
 Figure XIII - 4.5d: X-ray powder diffraction diagram of Eds6 = edisylate, form VI
 Figure XIV - 4.6a: X-ray powder diffraction diagram of Ise2 = isethionate, form II
 Figure XV - 4.6b: X-ray powder diffraction diagram of Ise4 = isethionate, form IV
 Figure XVI - 4.7a: X-ray powder diffraction diagram of Bes3 = besylate, form III (anhydrous form)
 Figure XVII - 4.7b: X-ray powder diffraction diagram of Bes5 = besylate, form V (anhydrous form)
 Figure XVIII - 4.8: X-ray powder diffraction diagram of Cas2 = camphorsulfonate, form II (anhydrous form)
 Figure XIX - 4.9a: X-ray powder diffraction diagram of Nds3 = naphthalene-1,5-disulfonate, form III
 Figure XX - 4.9b: X-ray powder diffraction diagram of Nds5 = naphthalene-1,5-disulfonate, form V
 Figure XXI - 4.10: X-ray powder diffraction diagram of Cit1 = citrate, form I
 Figure XXII - 4.11a: X-ray powder diffraction diagram of D-Tar1 = D-tartrate, form I
 Figure XXIII - 4.12a: X-ray powder diffraction diagram of L-Tar1 = L-tartrate, form I
 Figure XXIV - 4.11b: X-ray powder diffraction diagram of D-Tar2 = D-tartrate, form II
 Figure XXV - 4.12b: X-ray powder diffraction diagram of L-Tar2 = L-tartrate, form II
 Figure XXVI - 4.13a: X-ray powder diffraction diagram of Fum1 = fumarate, form I

Figure XXVII - 4.13b: X-ray powder diffraction diagram of Fum3 = fumarate, form III
 Figure XXVIII - 4.14: X-ray powder diffraction diagram of Mae1 = maleate, form I
 Figure XXIX - 4.15: X-ray powder diffraction diagram of Glc1 = glycolate, form I
 Figure XXX - 4.16: X-ray powder diffraction diagram of Gly1 = glycinate, form I
 Figure XXXI - 4.17a: X-ray powder diffraction diagram of L-Mal1 = L-malate, form I
 Figure XXXII - 4.18a: X-ray powder diffraction diagram of D-Mal1 = L-malate, form I
 Figure XXXIII - 4.17b: X-ray powder diffraction diagram of L-Mal2 = L-malate, form II
 Figure XXXIV - 4.18b: X-ray powder diffraction diagram of D-Mal3 = D-malate, form III
 Figure XXXV - 4.19a: X-ray powder diffraction diagram of Mao1 = malonate, form I
 Figure XXXVI - 4.19b: X-ray powder diffraction diagram of Mao2 = malonate, form II
 Figure XXXVII - 4.19c: X-ray powder diffraction diagram of Mao3 = malonate, form III
 Figure XXXVIII - 4.19d: X-ray powder diffraction diagram of Mao4 = malonate, form IV
 Figure XXXIX - 4.19e: X-ray powder diffraction diagram of Mao6 = malonate, form VI
 Figure XL - 4.20a: X-ray powder diffraction diagram of Suc1 = succinate, form I
 Figure XLI - 4.20b: X-ray powder diffraction diagram of Suc2 = succinate, form II
 Figure XLII - 4.21a: X-ray powder diffraction diagram of Oxa3 = oxalate, form III
 Figure XLIII - 4.21b: X-ray powder diffraction diagram of Oxa5 = oxalate, form V
 Figure XLIV - 4.21c: X-ray powder diffraction diagram of Oxa6 = oxalate, form VI
 Figure XLV - 4.22: X-ray powder diffraction diagram of Gen1 = gentisate, form I
 Figure XLVI - 4.23a: X-ray powder diffraction diagram of Cam2 = camphorate, form II
 Figure XLVII - 4.23b: X-ray powder diffraction diagram of Cam3 = camphorate, form III
 Figure XLVIII - 4.24a: X-ray powder diffraction diagram of Ben2 = benzoate, form II
 Figure XLIX - 4.24b: X-ray powder diffraction diagram of Ben3 = benzoate, form III
 Figure L - 4.25a: X-ray powder diffraction diagram of Sac3 = saccharinate, form III
 Figure LI - 4.25b: X-ray powder diffraction diagram of Sac5 = saccharinate, form V
 Figure LII - 4.26: X-ray powder diffraction diagram of Sal1 = salicylate, form I
 Figure LIII - 4.27a: X-ray powder diffraction diagram of L-Asp1 = L-aspartate, form I
 Figure LIV - 4.27b: X-ray powder diffraction diagram of L-Asp2 = L-aspartate, form II
 Figure LV - 4.28a: X-ray powder diffraction diagram of Asc1 = ascorbate, form I
 Figure LVI - 4.28b: X-ray powder diffraction diagram of Asc3 = ascorbate, form III
 Figure LVII - 4.28c: X-ray powder diffraction diagram of Asc4 = ascorbate, form IV

[0024] The values of the X-ray powder reflections (up to 30° 2 Θ) and intensities (normalized) as recorded for the crystalline salt forms in accordance with the present invention are displayed in the following Tables. For each crystalline salt form, the highest values of d[A] in the corresponding Table characterizes this crystalline salt form.

Table I - 4.1a X-ray powder reflections (up to 30° 2 Θ) and intensities (normalized) of HCl1 = chloride, form I (anhydrous)

2 Θ [°]	d [Å]	I/I ₀ [%]
6,03	14,65	100
8,78	10,07	15
9,06	9,76	11
10,90	8,12	18
11,42	7,75	13
12,08	7,33	93
12,58	7,04	7
13,79	6,42	22
15,06	5,88	12
16,82	5,27	75
17,50	5,07	74
18,36	4,83	98

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I ₀ [%]
5	18,99	4,67	32
	19,78	4,49	12
	20,27	4,38	53
	21,14	4,20	98
10	21,50	4,13	28
	21,96	4,05	71
	22,52	3,95	29
	22,99	3,87	55
15	23,74	3,75	30
	24,25	3,67	25
	25,34	3,51	14
20	25,98	3,43	10
	26,78	3,33	7
	27,34	3,26	9
	27,88	3,20	19
25	28,30	3,15	42
	29,07	3,07	52

30 **Table II - 4.1b X-ray powder reflections (up to 30° 2 Θ) and intensities (normalized) of HCl2 = chloride, form II (hydrated form)**

	2 Θ [°]	d [Å]	I/I ₀ [%]
35	5,56	15,88	92
	6,03	14,65	29
	10,06	8,79	47
	10,77	8,21	58
40	11,25	7,86	14
	11,69	7,57	20
	12,07	7,33	28
	13,45	6,58	21
45	14,50	0,00	17
	15,66	5,66	27
	16,43	5,39	25
50	16,73	5,30	41
	17,55	5,05	60
	17,73	5,00	64
55	18,14	4,89	99
	19,09	4,65	55
	19,69	4,51	43

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I _o [%]
5	20,49	4,34	45
	20,82	4,27	50
	21,72	4,09	37
	22,14	4,01	32
10	22,63	3,93	23
	23,18	3,84	37
	23,70	3,75	76
	23,96	3,71	100
15	25,45	3,50	28
	26,50	0,00	18
	27,31	3,27	42
20	28,46	3,14	33
	28,94	3,09	24
	29,82	3,00	21

Table III - 4.2a X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of HBr7 = bromide, form VII (anhydrous form)

	2 Θ [°]	d [Å]	I/I _o [%]
30	5,99	14,75	12
	6,15	14,35	24
	6,60	13,38	42
35	7,54	11,72	21
	8,82	10,01	12
	9,12	9,69	16
	9,55	9,26	34
40	9,85	8,97	41
	10,79	8,19	22
	11,60	7,63	52
45	11,92	7,42	18
	12,24	7,23	43
	14,19	6,24	30
	14,55	6,08	40
50	15,34	5,77	23
	16,06	5,51	38
	16,37	5,41	28
55	16,65	5,32	47
	16,98	5,22	37
	17,56	5,05	57

EP 2 364 968 A1

(continued)

	2θ [°]	d [Å]	I/I_0 [%]
5	17,96	4,94	51
	18,42	4,81	36
	18,80	4,72	17
10	19,08	4,65	13
	19,68	4,51	100
	20,17	4,40	70
15	20,57	4,31	27
	21,44	4,14	31
	21,72	4,09	48
20	22,37	3,97	55
	22,88	3,88	24
	23,39	3,80	68
25	23,90	3,72	53
	24,09	3,69	42
	24,38	3,65	33
30	24,60	3,62	34
	25,08	3,55	11
	25,64	3,47	10
35	26,26	3,39	15
	27,06	3,29	22
	27,75	3,21	23
40	28,32	3,15	15
	28,91	3,09	21
	29,52	3,02	14
	29,89	2,99	13

Table IV - 4.2b X-ray powder reflections (up to $30^\circ 2\theta$) and intensities (normalized) of HBr8 = bromide, form VIII

	2θ [°]	d [Å]	I/I_0 [%]
45	5,91	14,95	22
	8,81	10,03	35
	11,03	8,02	27
50	11,88	7,44	34
	13,58	6,51	13
	14,37	6,16	5
55	15,22	5,82	17
	16,06	5,51	3
	17,00	5,21	73
	17,61	5,03	52

EP 2 364 968 A1

(continued)

	2 θ [°]	d [Å]	I/I ₀ [%]
5	18,35	4,83	29
	18,85	4,70	64
	20,21	4,39	52
	21,09	4,21	34
10	21,68	4,10	100
	22,11	4,02	54
	22,91	3,88	58
	24,01	3,70	42
15	25,06	3,55	10
	25,56	3,48	11
	26,26	3,39	11
20	27,65	3,22	37
	29,28	3,05	43

Table V - 4.3 X-ray powder reflections (up to 30 ° 2 θ) and intensities (normalized) of Pho1 = phosphate, form I

	2 θ [°]	d [Å]	I/I ₀ [%]
25	3,23	27,30	9
	5,62	15,72	44
30	5,85	15,09	16
	7,75	11,39	7
	8,11	10,90	48
35	9,04	9,77	20
	9,42	9,38	14
	9,98	8,86	8
	10,38	8,51	21
40	10,62	8,33	14
	11,24	7,87	75
	11,61	7,61	27
45	11,89	7,43	24
	13,68	6,47	41
	13,95	6,34	14
	14,49	6,11	7
50	14,94	5,92	24
	15,79	5,61	36
	16,29	5,44	36
55	16,88	5,25	34
	17,11	5,18	36
	17,39	5,10	20

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I _o [%]
5	17,63	5,03	35
	17,93	4,94	39
	18,34	4,83	24
	18,53	4,78	23
10	18,88	4,70	41
	19,51	4,55	100
	20,23	4,39	40
	20,60	4,31	50
15	21,23	4,18	46
	21,71	4,09	24
	22,37	3,97	73
20	22,66	3,92	27
	23,21	3,83	26
	23,37	3,80	40
	23,98	3,71	27
25	24,33	3,65	23
	24,91	3,57	13
	25,36	3,51	13
30	25,76	3,46	19
	26,29	3,39	9
	26,91	3,31	8
	27,35	3,26	48
35	27,98	3,19	15
	28,38	3,14	9
	29,03	3,07	13
40	29,48	3,03	11
	29,73	3,00	11

45 **Table VI - 4.4a X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Sul1 = sulfate, form I (hydrated form)**

	2 Θ [°]	d [Å]	I/I _o [%]
50	4,60	19,21	100
	8,82	10,02	3
	11,80	7,49	5
	12,06	7,33	14
55	13,75	6,44	15
	14,01	6,32	5
	14,84	5,96	7

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I_o [%]
5	15,57	5,69	5
	17,06	5,19	6
	17,79	4,98	15
10	18,35	4,83	4
	18,68	4,75	8
	19,43	4,56	3
15	20,38	4,35	15
	21,43	4,14	16
	21,86	4,06	2
20	22,47	3,95	3
	22,95	3,87	8
	23,38	3,80	10
25	23,90	3,72	11
	24,30	3,66	4
	25,14	3,54	4
30	25,62	3,47	5
	25,96	3,43	6
	27,42	3,25	12
35	28,31	3,15	3
	29,10	3,07	4
	29,70	3,01	1
	30,25	2,95	3

Table VII - 4.4b X-ray powder reflections (up to 30° 2 Θ) and intensities (normalized) of Sul5 = sulfate, form V

	2 Θ [°]	d [Å]	I/I_o [%]
40	4,96	17,82	17
	7,67	11,52	83
	8,78	10,07	100
45	10,90	8,11	5
	12,24	7,23	5
	13,06	6,77	18
50	13,64	6,49	20
	14,72	6,01	16
	15,32	5,78	19
55	15,92	5,56	16
	16,32	5,43	9
	16,76	5,29	15
	17,54	5,05	23

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I _o [%]
5	18,07	4,90	7
	18,35	4,83	16
	18,93	4,68	14
	19,30	4,59	24
10	19,84	4,47	12
	20,36	4,36	86
	21,04	4,22	8
	21,21	4,19	4
15	21,66	4,10	18
	22,54	3,94	6
	22,90	3,88	20
20	23,14	3,84	29
	23,68	3,75	31
	23,95	3,71	8
25	24,54	3,62	10
	24,81	3,59	18
	25,42	3,50	19
	26,18	3,40	13
30	26,52	3,36	11
	26,83	3,32	12
	27,58	3,23	10
35	28,00	3,18	12
	28,45	3,13	6
	28,97	3,08	4
40	29,51	3,02	20

Table VIII - 4.4c X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Sul6 = sulfate, form VI (hydrated form)

	2 Θ [°]	d [Å]	I/I _o [%]
45	5,63	15,70	30
	6,04	14,63	19
	6,66	13,26	15
50	7,63	11,57	10
	9,51	9,29	60
	10,22	8,65	4
55	10,72	8,25	7
	11,22	7,88	44
	12,09	7,32	43

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I₀ [%]
5	12,86	6,88	3
	13,59	6,51	89
	14,00	6,32	21
	14,93	5,93	8
10	15,31	5,78	24
	15,82	5,60	5
	16,27	5,44	36
	16,82	5,27	87
15	17,58	5,04	3
	18,41	4,82	48
	19,01	4,66	44
20	19,82	4,48	100
	20,71	4,29	22
	21,40	4,15	35
25	22,07	4,02	11
	22,99	3,86	21
	23,41	3,80	19
	23,83	3,73	36
30	24,25	3,67	12
	25,14	3,54	5
	25,37	3,51	5
35	25,67	3,47	7
	26,25	3,39	7
	26,74	3,33	10
	27,54	3,24	16
40	27,95	3,19	15
	28,19	3,16	15
	28,71	3,11	4
45	29,26	3,05	6
	29,82	2,99	4

Table IX - 4.4d X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Sul7 = sulfate, form VII

50	2 Θ [°]	d [Å]	I/I₀ [%]
	5,50	16,06	11
	9,33	9,47	9
55	10,95	8,07	43
	11,41	7,75	23
	12,10	7,31	4

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I _o [%]
5	12,97	6,82	100
	13,46	6,57	13
	13,93	6,35	15
	14,22	6,22	8
10	16,20	5,47	49
	16,44	5,39	89
	17,27	5,13	9
	17,87	4,96	16
15	18,65	4,75	17
	19,02	4,66	12
	19,45	4,56	27
20	20,25	4,38	24
	20,71	4,29	25
	21,43	4,14	9
25	22,09	4,02	25
	22,47	3,95	16
	22,69	3,92	14
	23,78	3,74	22
30	24,12	3,69	16
	24,41	3,64	21
	25,13	3,54	6
35	25,63	3,47	18
	26,55	3,35	16
	26,93	3,31	8
	27,20	3,28	7
40	27,91	3,19	5
	28,21	3,16	3
	29,31	3,04	7
45	29,55	3,02	5

Table X - 4.5a X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Eds1 = edisylate, form I

	2 Θ [°]	d [Å]	I/I _o [%]
50	3,00	29,46	35
	3,57	24,76	10
	4,08	21,65	17
55	4,96	17,82	9
	5,85	15,10	19
	8,14	10,85	11

EP 2 364 968 A1

(continued)

	2θ [°]	d [Å]	I/I_0 [%]
5	8,50	10,39	12
	8,90	9,93	7
	9,36	9,45	15
	9,67	9,14	23
10	10,36	8,53	48
	11,35	7,79	13
	11,64	7,60	18
	12,18	7,26	27
15	12,60	7,02	25
	13,11	6,75	30
	14,07	6,29	21
	14,74	6,00	20
20	15,73	5,63	22
	15,99	5,54	38
	16,70	5,30	67
	17,51	5,06	100
25	17,98	4,93	23
	18,21	4,87	25
	18,92	4,69	26
	19,40	4,57	41
30	20,09	4,42	30
	20,78	4,27	80
	21,52	4,13	43
	21,86	4,06	55
35	22,46	3,95	26
	23,05	3,86	34
	23,20	3,83	38
	23,70	3,75	46
40	24,07	3,69	25
	24,47	3,63	34
	24,97	3,56	67
	25,51	3,49	30
45	25,92	3,44	19
	27,11	3,29	18
	28,34	3,15	12
	28,64	3,11	29
50	29,80	3,00	14

Table XI - 4.5b X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Eds2 = edisylate, form II

	2 Θ [°]	d [Å]	I/I ₀ [%]
5	3,00	29,44	59
	3,50	25,22	17
	4,08	21,62	26
	4,86	18,15	82
10	5,68	15,55	16
	5,95	14,83	26
	7,46	11,83	24
15	8,35	10,59	100
	9,15	9,66	22
	9,72	9,09	40
	11,27	7,84	32
20	12,14	7,28	19
	12,54	7,05	41
	12,97	6,82	18
25	13,35	6,63	24
	13,73	6,44	23
	14,24	6,21	15
	14,53	6,09	39
30	15,15	5,84	49
	15,80	5,60	38
	16,18	5,47	34
35	16,94	5,23	88
	17,60	5,04	31
	18,28	4,85	36
	19,50	4,55	84
40	20,80	4,27	95
	21,52	4,13	64
	22,38	3,97	79
45	23,04	3,86	52
	23,65	3,76	41
	24,49	3,63	46
	26,37	3,38	19
50	26,71	3,33	32
	27,44	3,25	56
	28,60	3,12	18
55	29,48	3,03	18

EP 2 364 968 A1

Table XII - 4.5c X-ray powder reflections (up to $30^\circ 2\Theta$) and intensities (normalized) of Eds5 = edisylate, form V

	$2\Theta [^\circ]$	$d [\text{\AA}]$	$I/I_0 [\%]$
5	3,46	25,51	100
	6,19	14,26	8
	7,84	11,27	5
10	9,62	9,18	9
	10,31	8,57	3
	10,87	8,13	4
15	11,91	7,43	6
	12,66	6,99	5
	12,99	6,81	4
20	13,24	6,68	4
	13,75	6,43	8
	14,17	6,25	4
25	14,80	5,98	6
	15,21	5,82	5
	15,72	5,63	7
30	16,63	5,33	16
	17,32	5,12	7
	17,88	4,96	10
35	18,61	4,76	13
	18,81	4,71	19
	19,33	4,59	11
40	19,73	4,50	8
	20,97	4,23	15
	21,50	4,13	18
45	22,08	4,02	11
	22,80	3,90	15
	23,21	3,83	6
50	23,78	3,74	16
	23,98	3,71	10
	24,38	3,65	8
55	24,89	3,57	6
	25,66	3,47	4
	25,87	3,44	3
	26,54	3,36	5
	27,34	3,26	4
	27,71	3,22	4
	28,63	3,12	1

EP 2 364 968 A1

Table XIII - 4.5d X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Eds6 = edisylate, form VI

	2 Θ [°]	d [Å]	I/I _o [%]
5	5,84	15,11	9
	7,41	11,93	1
	7,94	11,12	34
10	9,64	9,17	49
	9,89	8,93	20
	11,58	7,64	23
15	12,63	7,00	47
	13,23	6,69	21
	13,78	6,42	54
	15,86	5,58	56
20	16,27	5,44	11
	17,11	5,18	17
	17,39	5,10	27
25	17,89	4,96	78
	18,29	4,85	17
	18,74	4,73	37
	18,98	4,67	19
30	19,32	4,59	27
	19,82	4,48	37
	20,68	4,29	14
35	21,48	4,13	100
	22,53	3,94	23
	22,87	3,89	91
	23,22	3,83	73
40	24,00	3,71	18
	24,11	3,69	17
	24,46	3,64	11
45	25,08	3,55	11
	25,57	3,48	32
	26,00	3,42	14
	26,68	3,34	22
50	27,11	3,29	9
	29,00	3,08	11
	29,29	3,05	17
55	30,04	2,97	7

Table XIV - 4.6a X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Ise2 = isethionate, form II

	2 Θ [°]	d [Å]	I/I₀ [%]
5	5,12	17,23	11
	8,07	10,94	7
	9,29	9,52	4
10	9,99	8,85	18
	10,53	8,39	20
	12,15	7,28	4
15	13,74	6,44	7
	15,75	5,62	20
	16,68	5,31	48
	17,42	5,09	29
20	18,10	4,90	38
	18,66	4,75	24
	19,31	4,59	36
25	20,00	4,44	37
	20,42	4,35	50
	21,22	4,18	100
	23,11	3,85	35
30	24,22	3,67	12
	24,96	3,56	8
	25,33	3,51	10
35	26,50	3,36	9
	27,89	3,20	7
	29,20	3,06	21
40	30,02	2,97	4

Table XV - 4.6b X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Ise4 = isethionate, form IV

	2 Θ [°]	d [Å]	I/I₀ [%]
45	9,89	8,93	19
	10,99	8,04	10
	12,16	7,27	7
50	13,37	6,62	27
	14,50	6,10	10
	15,19	5,83	7
55	15,89	5,57	34
	16,59	5,34	27

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I _o [%]
5	17,14	5,17	13
	18,19	4,87	30
	18,61	4,76	23
10	19,92	4,45	100
	20,93	4,24	84
	21,60	4,11	25
15	21,97	4,04	30
	22,88	3,88	29
	24,06	3,70	11
20	24,95	3,57	12
	25,36	3,51	10
	26,27	3,39	18
25	26,72	3,33	11
	27,75	3,21	7
	28,40	3,14	5
30	29,46	3,03	12
	30,50	2,93	11

Table XVI - 4.7a X-ray powder reflections (up to 30° 2 Θ) and intensities (normalized) of Bes3 = besylate, form III

	2 Θ [°]	d [Å]	I/I _o [%]
35	7,33	12,05	3
	9,37	9,43	28
	10,89	8,12	3
40	11,73	7,54	10
	14,08	6,29	32
	14,84	5,96	11
45	15,30	5,78	22
	15,77	5,61	55
	17,58	5,04	16
50	18,55	4,78	100
	20,34	4,36	85
	21,27	4,17	19
55	21,88	4,06	32
	22,91	3,88	41
	24,03	3,70	26
60	24,61	3,61	11
	25,31	3,52	25
	26,72	3,33	3

EP 2 364 968 A1

(continued)

	2 θ [°]	d [Å]	I/I _o [%]
5	26,72	3,33	3
	28,11	3,17	10
	28,61	3,12	6
	29,41	3,03	19
10	30,26	2,95	6

Table XVII - 4.7b X-ray powder reflections (up to 30 ° 2 θ) and intensities (normalized) of Bes5 = besylate, form V

	2 θ [°]	d [Å]	I/I _o [%]
15	5,90	14,96	1
	6,59	13,40	6
	7,49	11,80	1
20	8,67	10,19	15
	9,06	9,75	10
	9,37	9,43	14
25	9,88	8,95	1
	10,11	8,74	2
	10,78	8,20	6
30	11,60	7,62	18
	11,99	7,38	4
	12,25	7,22	5
	12,91	6,85	6
35	13,80	6,41	12
	14,09	6,28	21
	14,85	5,96	5
40	15,31	5,78	6
	15,75	5,62	23
	16,55	5,35	11
	16,93	5,23	12
45	17,41	5,09	16
	17,52	5,06	16
	17,94	4,94	30
50	18,46	4,80	100
	18,98	4,67	14
	19,70	4,50	18
	20,17	4,40	27
55	21,27	4,17	19
	21,65	4,10	21
	21,97	4,04	9

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I _o [%]
5	22,86	3,89	14
	23,48	3,79	6
	24,01	3,70	7
10	24,61	3,61	8
	25,13	3,54	5
	25,38	3,51	6
15	26,29	3,39	3
	26,63	3,34	5
	26,86	3,32	5
20	27,35	3,26	2
	28,00	3,18	8
	28,72	3,11	6
25	29,37	3,04	11
	29,74	3,00	6

Table XVIII - 4.8 X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Cas2 = camphorsulfonate, form II

	2 Θ [°]	d [Å]	I/I _o [%]
30	3,84	22,97	5
	4,71	18,74	20
	5,90	14,98	24
35	7,43	11,90	9
	7,67	11,52	24
	9,39	9,41	9
40	10,51	8,41	2
	10,90	8,11	24
	11,26	7,85	4
45	11,75	7,52	10
	12,50	7,08	11
	12,81	6,90	100
50	13,52	6,54	45
	14,12	6,27	5
	14,99	5,91	16
55	15,44	5,73	26
	16,03	5,53	20
	16,54	5,36	4
	17,23	5,14	16
	17,62	5,03	39

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I_o [%]
5	18,05	4,91	28
	18,69	4,74	18
	19,20	4,62	12
10	19,77	4,49	52
	21,22	4,18	46
	22,00	4,04	18
15	22,39	3,97	28
	22,71	3,91	45
	23,94	3,71	7
20	24,60	3,62	41
	25,32	3,51	8
	25,80	3,45	6
25	26,30	3,39	22
	27,10	3,29	22
	27,55	3,23	9
30	28,73	3,10	18
	29,26	3,05	11
	29,67	3,01	10
	30,28	2,95	9

Table XIX - 4.9a X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Nds3 = naphthalene-1,5-disulfonate, form III

	2 Θ [°]	d [Å]	I/I_o [%]
35	5,45	16,20	7
	5,76	15,32	5
	6,53	13,52	4
40	9,00	9,81	3
	9,39	9,41	41
	9,98	8,86	5
45	10,41	8,49	4
	10,90	8,11	6
	11,17	7,91	5
50	11,52	7,68	14
	12,96	6,83	10
	13,71	6,46	10
55	14,38	6,15	4
	14,84	5,96	2
	15,18	5,83	2

EP 2 364 968 A1

(continued)

	2θ [°]	d [Å]	I/I_0 [%]
5	15,92	5,56	23
	16,57	5,34	3
	16,82	5,27	5
	17,28	5,13	13
10	18,00	4,93	11
	18,31	4,84	15
	18,83	4,71	34
	19,10	4,64	100
15	19,57	4,53	19
	20,04	4,43	6
	20,46	4,34	6
20	21,27	4,17	12
	22,13	4,01	8
	22,35	3,98	10
	22,88	3,88	22
25	23,18	3,83	36
	23,59	3,77	20
	24,15	3,68	21
30	24,46	3,64	5
	25,19	3,53	8
	26,46	3,37	3
	26,85	3,32	4
35	27,36	3,26	3
	28,14	3,17	3
	28,62	3,12	20
40	29,48	3,03	5
	29,96	2,98	4

45 **Table XX - 4.9b X-ray powder reflections (up to 30 ° 2θ) and intensities (normalized) of Nds5 = naphthalene-1,5-disulfonate, form V**

	2θ [°]	d [Å]	I/I_0 [%]
50	5,77	15,30	46
	6,98	12,65	37
	8,97	9,86	11
	11,27	7,85	61
55	12,31	7,19	8
	13,93	6,35	27
	14,69	6,02	21

EP 2 364 968 A1

(continued)

	20 [°]	d [Å]	I/I _o [%]
5	15,58	5,68	23
	16,43	5,39	18
	16,75	5,29	20
10	18,35	4,83	36
	19,18	4,62	28
	19,58	4,53	27
15	20,62	4,30	65
	21,11	4,21	66
	22,26	3,99	100
20	22,73	3,91	67
	23,90	3,72	9
	25,09	3,55	31
25	26,23	3,39	8
	26,85	3,32	8
	27,08	3,29	9
30	28,88	3,09	14
	29,68	3,01	11

Table XXI - 4.10 X-ray powder reflections (up to 30 ° 2θ) and intensities (normalized) of Cit1 = citrate, form I

	2 θ [°]	d [Å]	I/I _o [%]
35	5,86	15,06	12
	7,39	11,96	16
	9,29	9,51	25
40	9,53	9,27	24
	10,99	8,04	3
	11,66	7,59	11
45	12,42	7,12	2
	13,66	6,48	35
	13,83	6,40	38
50	14,74	6,01	17
	15,69	5,64	3
	16,04	5,52	10
55	16,97	5,22	4
	17,36	5,10	14
	17,59	5,04	28
60	18,59	4,77	25
	19,55	4,54	100
	20,46	4,34	7

EP 2 364 968 A1

(continued)

	$2\theta [^\circ]$	$d [\text{\AA}]$	$I/I_0 [\%]$
5	21,04	4,22	12
	21,66	4,10	35
	22,30	3,98	6
	22,79	3,90	14
10	23,23	3,83	14
	23,73	3,75	23
	24,55	3,62	6
	25,38	3,51	4
15	26,10	3,41	6
	26,53	3,36	4
	27,68	3,22	8
20	28,02	3,18	4
	28,98	3,08	6
	29,32	3,04	11
	29,94	2,98	4
25	30,51	2,93	7

Table XXII - 4.11a X-ray powder reflections (up to $30^\circ 2\theta$) and intensities (normalized) of D-Tar1 = D-tartrate, form I

	$2\theta [^\circ]$	$d [\text{\AA}]$	$I/I_0 [\%]$
30	4,87	18,14	1
	5,42	16,28	7
35	6,02	14,66	3
	8,98	9,84	8
	9,70	9,11	33
40	10,77	8,21	27
	11,10	7,96	6
	11,54	7,66	4
	12,41	7,13	3
45	13,07	6,77	48
	14,02	6,31	4
	15,23	5,81	12
50	16,15	5,48	25
	17,34	5,11	15
	17,98	4,93	68
	18,82	4,71	16
55	19,11	4,64	29
	19,44	4,56	43

EP 2 364 968 A1

(continued)

	2Θ [°]	d [Å]	I/I_0 [%]
5	20,09	4,42	6
	20,74	4,28	100
	22,00	4,04	50
10	22,35	3,98	49
	22,78	3,90	16
	23,69	3,75	6
15	24,34	3,65	10
	25,66	3,47	9
	26,38	3,38	13
20	26,98	3,30	20
	27,89	3,20	6
	28,42	3,14	10
25	29,08	3,07	9
	29,43	3,03	9
	29,81	2,99	12

Table XXIII - 4.12a X-ray powder reflections (up to $30^\circ 2\Theta$) and intensities (normalized) of L-Tar1 = L-tartrate, form I

	2Θ [°]	d [Å]	I/I_0 [%]
30	5,43	16,28	9
	9,12	9,69	12
	9,64	9,17	44
35	10,28	8,60	8
	10,75	8,22	65
	11,28	7,84	14
40	11,62	7,61	9
	12,35	7,16	10
	13,17	6,72	100
45	14,03	6,31	8
	15,24	5,81	32
	16,13	5,49	44
50	17,25	5,14	25
	17,93	4,94	52
	18,24	4,86	85
55	18,75	4,73	31
	19,30	4,60	90
	19,83	4,47	35
	20,60	4,31	36

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I_o [%]
5	20,96	4,24	90
	21,58	4,12	18
	22,11	4,02	60
10	22,64	3,92	84
	23,25	3,82	19
	23,64	3,76	7
15	24,13	3,69	13
	24,46	3,64	8
	25,09	3,55	3
20	25,51	3,49	13
	26,26	3,39	21
	27,31	3,26	40
25	27,69	3,22	24
	28,29	3,15	10
	28,73	3,10	6
30	29,00	3,08	6
	29,48	3,03	5
	29,85	2,99	12
	30,03	2,97	14

Table XXIV - 4.11 b X-ray powder reflections (up to 30° 2 Θ) and intensities (normalized) of D-Tar2 = D-tartrate, form II

	2 Θ [°]	d [Å]	I/I_o [%]
35	5,50	16,05	6
	9,54	9,26	7
	9,93	8,90	18
40	10,96	8,07	58
	12,12	7,29	26
	12,85	6,89	12
45	13,32	6,64	88
	13,85	6,39	9
	14,39	6,15	40
50	15,23	5,81	15
	16,07	5,51	59
	16,46	5,38	100
55	16,99	5,21	5
	18,10	4,90	41
	18,59	4,77	15

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I_o [%]
5	19,22	4,61	27
	19,94	4,45	72
	20,92	4,24	87
10	21,33	4,16	11
	21,85	4,06	26
	22,32	3,98	28
15	22,76	3,90	31
	23,13	3,84	29
	23,61	3,76	15
20	23,94	3,71	12
	24,29	3,66	18
	24,67	3,61	12
25	25,14	3,54	24
	26,27	3,39	24
	26,68	3,34	32
30	26,95	3,31	11
	27,61	3,23	15
	28,39	3,14	8
35	28,90	3,09	9
	29,46	3,03	16
	30,38	2,94	24

Table XXV - 4.12b X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of L-Tar2 = L-tartrate, form II

	2 Θ [°]	d [Å]	I/I_o [%]
40	5,48	16,13	9
	9,55	9,25	6
	9,93	8,90	19
45	10,95	8,07	49
	12,12	7,30	26
	12,83	6,89	12
50	13,32	6,64	89
	13,85	6,39	7
	14,38	6,15	42
55	15,24	5,81	16
	16,07	5,51	63
	16,45	5,38	88
	16,99	5,21	6

EP 2 364 968 A1

(continued)

	2 θ [°]	d [Å]	I/I _o [%]
5	18,09	4,90	39
	18,58	4,77	14
	19,23	4,61	31
	19,94	4,45	82
10	20,93	4,24	100
	21,31	4,17	14
	21,85	4,06	32
15	22,31	3,98	32
	22,75	3,91	32
	23,11	3,85	30
	23,60	3,77	17
20	23,94	3,71	11
	24,28	3,66	20
	24,72	3,60	13
25	25,12	3,54	27
	26,28	3,39	24
	26,67	3,34	33
	27,60	3,23	11
30	28,36	3,14	8
	28,80	3,10	7
	29,02	3,07	9
35	29,46	3,03	16
	29,84	2,99	7
	30,37	2,94	25

Table XXVI - 4.13a X-ray powder reflections (up to 30 ° 2 θ) and intensities (normalized) of Fum1 = fumarate, form I

	2 θ [°]	d [Å]	I/I _o [%]
45	5,46	16,18	19
	7,94	11,12	12
	8,72	10,13	70
	10,43	8,47	3
50	11,20	7,89	3
	12,17	7,26	16
	12,90	6,86	4
55	13,63	6,49	3
	13,98	6,33	4
	14,64	6,05	20

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I_o [%]
5	15,24	5,81	6
	15,88	5,58	5
	16,26	5,45	33
	16,73	5,30	18
10	17,50	5,06	4
	17,68	5,01	6
	18,02	4,92	8
	18,98	4,67	30
15	19,50	4,55	6
	20,32	4,37	23
	21,16	4,19	100
20	21,55	4,12	25
	21,93	4,05	14
	22,40	3,97	19
	22,73	3,91	10
25	23,10	3,85	30
	24,06	3,70	5
	24,33	3,66	2
30	25,43	3,50	41
	26,02	3,42	6
	26,40	3,37	6
	27,00	3,30	2
35	27,32	3,26	2
	27,93	3,19	1
	28,66	3,11	9
40	29,29	3,05	8
	29,49	3,03	5

45 **Table XXVII - 4.13b X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Fum3 = fumarate, form III**

	2 Θ [°]	d [Å]	I/I_o [%]
50	6,21	14,22	51
	7,30	12,09	39
	9,41	9,39	49
	9,70	9,11	50
55	10,05	8,79	20
	11,37	7,78	11
	12,23	7,23	10

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I_o [%]
5	13,18	6,71	19
	13,55	6,53	6
	14,17	6,24	35
	14,60	6,06	92
10	15,33	5,78	17
	15,65	5,66	42
	17,38	5,10	26
15	18,06	4,91	6
	18,62	4,76	20
	18,79	4,72	23
	19,44	4,56	67
20	19,89	4,46	100
	20,65	4,30	97
	21,49	4,13	73
25	22,73	3,91	71
	23,73	3,75	15
	24,11	3,69	18
	24,55	3,62	9
30	25,01	3,56	6
	25,45	3,50	9
	26,26	3,39	21
35	26,50	3,36	11
	27,30	3,26	4
	28,43	3,14	4
	28,68	3,11	7
40	28,95	3,08	6
	29,81	2,99	15

45 **Table XXVIII - 4.14 X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Mae1 = maleate, form I**

	2 Θ [°]	d [Å]	I/I_o [%]
50	5,52	15,99	9
	8,43	10,48	5
	9,26	9,55	8
	10,35	8,54	4
55	10,79	8,19	21
	11,01	8,03	18
	12,04	7,35	8

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I _o [%]
5	12,51	7,07	14
	12,72	6,95	32
	13,07	6,77	6
	13,64	6,49	10
10	14,12	6,27	11
	15,21	5,82	8
	15,71	5,64	11
15	16,54	5,35	45
	17,31	5,12	11
	17,55	5,05	28
	17,83	4,97	67
20	18,60	4,77	24
	19,19	4,62	42
	19,50	4,55	100
25	20,06	4,42	54
	20,91	4,24	9
	21,58	4,12	38
	22,19	4,00	15
30	22,46	3,96	12
	23,19	3,83	6
	23,78	3,74	14
35	24,37	3,65	11
	25,16	3,54	16
	25,50	3,49	9
	26,35	3,38	11
40	27,50	3,24	11
	27,99	3,18	12
	28,65	3,11	7
45	29,16	3,06	10
	30,00	2,98	5
	30,30	2,95	14

Table XXIX - 4.15 X-ray powder reflections (up to 30° 2 Θ) and intensities (normalized) of Glc1 = glycolate, form I

	2 Θ [°]	d [Å]	I/I _o [%]
50	5,15	17,14	26
55	9,04	9,78	74
	10,74	8,23	4
	11,71	7,55	4

EP 2 364 968 A1

(continued)

	2 θ [°]	d [Å]	I/I_o [%]
5	13,75	6,44	31
	14,66	6,04	9
	15,45	5,73	5
	15,75	5,62	8
10	16,60	5,34	19
	17,12	5,17	5
	17,54	5,05	25
	17,88	4,96	12
15	18,21	4,87	6
	18,84	4,71	19
	18,98	4,67	17
20	19,72	4,50	3
	20,12	4,41	17
	20,51	4,33	21
	21,29	4,17	55
25	21,87	4,06	100
	22,60	3,93	9
	23,19	3,83	35
30	23,78	3,74	11
	24,30	3,66	9
	24,74	3,60	9
35	25,34	3,51	10
	26,03	3,42	4
	27,02	3,30	10
	27,95	3,19	9
40	28,17	3,17	11
	28,96	3,08	3
	29,51	3,02	3
45	29,74	3,00	4
	30,51	2,93	7

Table XXX - 4.16 X-ray powder reflections (up to 30° 2 θ) and intensities (normalized) of Gly1 = glycinate, form I

50	2 θ [°]	d [Å]	I/I_o [%]
	6,31	14,00	10
	10,34	8,55	2
55	10,79	8,19	6
	11,36	7,78	59
	11,67	7,58	10

EP 2 364 968 A1

(continued)

	2 θ [°]	d [Å]	I/I_o [%]
5	12,10	7,31	14
	12,56	7,04	31
	12,91	6,85	19
	13,14	6,73	33
10	14,53	6,09	33
	15,24	5,81	11
	15,96	5,55	14
	16,88	5,25	32
15	17,11	5,18	34
	17,67	5,02	9
	18,18	4,88	100
20	18,57	4,77	11
	19,01	4,66	10
	19,47	4,56	30
	20,02	4,43	16
25	21,12	4,20	46
	22,00	4,04	74
	22,66	3,92	10
30	23,13	3,84	14
	23,71	3, 75	20
	24,58	3,62	23
35	25,31	3,52	47
	26,25	3,39	39
	26,76	3,33	16
	27, 76	3,21	18
40	28,05	3,18	10
	28,45	3,13	8
	28,89	3,09	9
45	29, 54	3,02	11
	29,98	2,98	11

Table XXXI - 4.17a X-ray powder reflections (up to 30 ° 2 θ) and intensities (normalized) of L-Mal1 = L-malate, form I

	2 θ [°]	d [Å]	I/I_o [%]
50	9,11	9,70	17
	9,12	9,69	18
55	9,81	9,01	35
	10,38	8,51	14

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I_o [%]
5	10,83	8,16	35
	11,54	7,66	32
	12,46	7,10	10
	12,62	7,01	14
10	13,26	6,67	16
	13,57	6,52	7
	14,46	6,12	26
	14,89	5,94	13
15	15,48	5,72	6
	15,85	5,59	19
	16,28	5,44	45
20	16,62	5,33	22
	17,23	5,14	13
	18,24	4,86	59
	18,83	4,71	26
25	19,67	4,51	83
	20,09	4,42	100
	20,36	4,36	59
30	21,05	4,22	85
	21,47	4,14	15
	22,46	3,95	41
	23,28	3,82	40
35	23,88	3,72	24
	24,71	3,60	12
	25,47	3,49	39
40	26,47	3,36	12
	27,30	3,26	12
	27,88	3,20	17
	28,43	3,14	7
45	28,83	3,09	10
	29,21	3,05	10
	29,62	3,01	32
50	30,29	2,95	24

Table XXXII - 4.18a X-ray powder reflections (up to 30° 2 Θ) and intensities (normalized) of D-Mal1 = D-malate, form I

	2 Θ [°]	d [Å]	I/I_o [%]
55	8,62	10,25	8

EP 2 364 968 A1

(continued)

	2 θ [°]	d [Å]	I/I ₀ [%]
5	9,13	9,67	19
	9,43	9,37	11
	9,81	9,01	60
10	10,41	8,49	11
	10,82	8,17	42
	11,52	7,68	51
15	12,61	7,01	15
	13,22	6,69	21
	13,54	6,54	11
20	14,47	6,12	26
	14,92	5,93	12
	15,82	5,60	20
25	16,28	5,44	62
	16,59	5,34	37
	17,24	5,14	20
30	18,22	4,87	77
	18,82	4,71	30
	19,67	4,51	91
35	20,09	4,42	100
	20,38	4,35	59
	20,64	4,30	41
40	21,06	4,22	95
	21,46	4,14	18
	22,48	3,95	45
45	23,29	3,82	48
	23,88	3,72	23
	24,72	3,60	14
50	25,45	3,50	56
	25,88	3,44	13
	26,45	3,37	13
55	27,28	3,27	10
	27,87	3,20	17
	28,40	3,14	6
	28,82	3,10	8
	29,15	3,06	9
	29,62	3,01	31
	30,13	2,96	17
	30,30	2,95	19

EP 2 364 968 A1

Table XXXIII - 4.17b X-ray powder reflections (up to 30° 2 θ) and intensities (normalized) of L-Mal2 = L-malate, form II

	2 θ [°]	d [Å]	I/I _o [%]
5	9,52	9,28	10
	9,91	8,92	5
	12,19	7,26	8
10	12,81	6,90	1
	13,38	6,61	40
	13,87	6,38	3
15	14,46	6,12	10
	15,22	5,82	7
	15,95	5,55	61
	16,65	5,32	4
20	18,08	4,90	6
	18,30	4,85	5
	18,68	4,75	3
25	19,10	4,64	21
	20,00	4,44	33
	20,96	4,24	100
	21,61	4, 11	5
30	22,23	4,00	13
	22,74	3,91	12
	23, 11	3,84	22
35	23,54	3,78	6
	24, 11	3,69	22
	24,52	3,63	6
	24,96	3,56	17
40	25,32	3,52	8
	26,26	3,39	24
	26,71	3,33	10
45	27,04	3,29	2
	27,74	3,21	1
	27,98	3,19	2
	28,38	3,14	13
50	29,17	3,06	3
	29,54	3,02	12
	29,87	2,99	7
55	30,54	2,93	9

EP 2 364 968 A1

Table XXXIV - 4.18b X-ray powder reflections (up to 30° 2 Θ) and intensities (normalized) of D-Mal3 = D-malate, form III

	2 Θ [°]	d [Å]	I/I _o [%]
5	5,54	15,94	9
	9,15	9,66	5
	9,54	9,26	14
10	9,90	8,93	24
	11,04	8,00	50
	11,53	7,67	9
15	12,21	7,25	17
	12,83	6,90	8
	13,38	6,61	78
	13,87	6,38	13
20	14,49	6, 11	24
	15,20	5,83	15
	15,74	5,63	23
25	15,97	5,54	47
	16,59	5,34	100
	16,98	5,22	7
	17,26	5,13	5
30	18,27	4,85	28
	18,69	4,74	15
	19,17	4,63	28
35	19,91	4,46	57
	20,95	4,24	75
	21,58	4,12	31
	22,18	4,00	30
40	23,08	3,85	35
	23,38	3,80	16
	23,57	3,77	14
45	23,94	3,71	17
	24, 11	3,69	20
	24,47	3,63	12
	24,98	3,56	20
50	25,42	3,50	9
	26,30	3,39	32
	26,70	3,34	23
55	27,08	3,29	6
	27,84	3,20	16
	28,45	3,13	10

EP 2 364 968 A1

(continued)

2 Θ [°]	d [Å]	I/I _o [%]
29,21	3,05	9
29,51	3,02	16
30,02	2,97	7
30,53	2,93	20

Table XXXV - 4.19a X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Mao1 = malonate, form I

2 Θ [°]	d [Å]	I/I _o [%]
8,66	10,20	13
9,08	9,74	12
9,47	9,34	16
10, 79	8,19	11
11,56	7,65	21
12,76	6,93	9
13,62	6,49	14
14,29	6,20	12
15,15	5,84	11
15, 98	5,54	17
16,38	5,41	17
16,63	5,33	16
17,15	5,17	19
17,64	5,02	9
18,31	4,84	20
19,16	4,63	50
19,55	4,54	28
19,97	4,44	56
20,06	4,42	60
20,29	4,37	65
20,98	4,23	100
21,46	4,14	27
21,87	4,06	31
22,19	4,00	69
22,95	3,87	36
23,29	3,82	16
24,34	3,65	9
24,84	3,58	25
25,24	3,53	20
28,28	3,15	7

EP 2 364 968 A1

(continued)

2 Θ [°]	d [Å]	I/I _o [%]
28,77	3,10	22
29,75	3,00	15

Table XXXVI - 4.19b X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Mao2 = malonate, form II

2 Θ [°]	d [Å]	I/I _o [%]
5,21	16,94	26
8,14	10,85	8
8,42	10,49	24
8,64	10,23	35
9,12	9,68	8
9,42	9,38	14
9,86	8,96	12
10,41	8,49	9
10,87	8,13	7
11,47	7,71	26
12,49	7,08	19
12,87	6,87	12
13,41	6,60	5
14,13	6,26	18
15,02	5,89	8
15,54	5,70	21
15,99	5,54	24
16,44	5,39	13
16,87	5,25	20
17,25	5,14	87
17,74	5,00	15
18,23	4,86	16
18,87	4,70	15
19,55	4,54	33
19,92	4,45	36
20,32	4,37	14
20,85	4,26	95
21,39	4,15	28
21,86	4,06	100
22,20	4,00	56
22,65	3,92	38
23,57	3,77	13

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I _o [%]
5	24,09	3,69	10
	24,91	3,57	30
	25,13	3,54	37
	25, 74	3,46	8
10	26,18	3,40	11
	26,57	3,35	8
	27,28	3,27	14
	28,22	3,16	8
15	28,89	3,09	5
	29,58	3,02	11
	29,92	2,98	13

Table XXXVII - 4.19c X-ray powder reflections (up to 30° 2 Θ) and intensities (normalized) of Mao3 = malonate, form III

	2 Θ [°]	d [Å]	I/I _o [%]
25	5,10	17,31	3
	5,55	15,92	16
	5,92	14,93	3
30	8,29	10,65	5
	9,07	9,74	3
	9,41	9,39	13
	10,09	8,76	11
35	10,62	8, 32	5
	11,06	8,00	37
	11,68	7,57	12
40	13,16	6,72	80
	13,83	6,40	6
	14,15	6,26	20
	15,34	5,77	3
45	15,74	5,63	12
	16,13	5,49	34
	16,62	5,33	100
50	17, 32	5,12	5
	18,05	4,91	22
	18,87	4,70	24
	19,53	4,54	23
55	20,30	4,37	73
	20, 77	4,27	13

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I_o [%]
5	21,11	4,21	15
	21,52	4,13	13
	22,65	3,92	37
10	22,90	3,88	32
	23,22	3,83	24
	24,32	3,66	13
15	24,83	3,58	8
	25,38	3,51	21
	25,88	3,44	19
20	26,17	3,40	16
	26,66	3, 34	9
	27,31	3,26	17
25	27,93	3,19	8
	28,18	3,16	9
	28,75	3,10	7
30	29,22	3,05	7
	29,60	3,02	6
	30,09	2,97	15

Table XXXVIII - 4.19d X-ray powder reflections (up to 30° 2 Θ) and intensities (normalized) of Mao4 = malonate, form IV

	2 Θ [°]	d [Å]	I/I_o [%]
35	5,03	17,55	20
	6,58	13,42	46
	8,28	10,67	8
40	8,54	10,35	7
	9,09	9,72	14
	9,51	9,30	34
45	9,98	8,85	12
	10,78	8,20	27
	11,29	7,83	15
50	11,59	7,63	23
	11,83	7,48	11
	12,22	7,24	35
55	13,13	6,74	18
	13,65	6,48	15
	14,09	6,28	16
	14,45	6,12	6

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I _o [%]
5	15,29	5,79	20
	15,90	5,57	8
	16,64	5,32	66
	17,58	5,04	60
10	18,02	4,92	53
	18,37	4,83	42
	19,11	4,64	52
	19,78	4,48	43
15	20,19	4,39	100
	21,23	4,18	38
	22,27	3,99	59
20	22,68	3,92	43
	22,95	3, 87	40
	23,42	3,80	50
25	24,05	3,70	18
	24, 58	3,62	23
	24,87	3,58	13
	25,34	3,51	39
30	26,38	3,38	15
	26,82	3,32	10
	27,90	3,20	10
35	28,44	3,14	9
	28,74	3,10	21
	29,70	3,01	12
40	30,27	2,95	18

Table XXXIX - 4.19e X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Mao6 = malonate, form VI

	2 Θ [°]	d [Å]	I/I _o [%]
45	2,81	31,37	11
	5,48	16,11	46
	8,26	10,70	16
50	9, 11	9,70	39
	10,29	8,59	7
	10,66	8,29	24
55	11,62	7,61	30
	12,55	7,05	8
	12,96	6,83	11

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I _o [%]
5	13,58	6,51	19
	13,86	6,38	9
	14,67	6,04	15
	15,37	5,76	15
10	15,89	5,57	18
	16,50	5,37	77
	17,00	5,21	31
	17,91	4,95	20
15	18,23	4,86	18
	18,92	4,69	17
	19,51	4,55	22
20	20,16	4,40	19
	20,79	4,27	81
	21,14	4,20	29
25	21,89	4,06	100
	22,41	3,96	55
	22,87	3,89	51
	23,46	3, 79	14
30	24,17	3,68	14
	24,80	3,59	30
	25,06	3,55	33
35	25,49	3,49	15
	26,26	3,39	14
	27,34	3,26	14
	29,45	3,03	8
40	29,94	2,98	21

Table XL - 4.20a X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Suc1 = succinate, form I

	2 Θ [°]	d [Å]	I/I _o [%]
45	5,99	14, 74	21
	7,31	12,09	4
50	8,34	10,59	2
	8,78	10,06	3
	9,27	9,53	29
55	9,57	9,23	15
	9,97	8,86	8
	10,35	8,54	7

EP 2 364 968 A1

(continued)

	2 θ [°]	d [Å]	I/I_o [%]
5	11,38	7,77	12
	11,66	7,58	5
	11,94	7,41	4
	12,75	6,94	5
10	13,69	6,46	31
	14,20	6,23	12
	14,58	6,07	13
	14,79	5,99	9
15	15,05	5,88	8
	15,95	5,55	11
	16,65	5,32	4
20	16,89	5,24	6
	17,16	5,16	8
	17,90	4,95	15
	18,60	4,77	24
25	19,22	4,61	30
	19,53	4,54	61
	19,99	4,44	100
30	21,03	4,22	26
	21,78	4,08	3
	22,16	4,01	20
	22,94	3,87	18
35	23, 79	3,74	8
	24,42	3,64	8
	25,17	3,54	3
40	25,48	3,49	5
	25,89	3,44	10
	27,23	3,27	7
	27,69	3,22	4
45	28,35	3,15	5
	28,97	3,08	4
	29,54	3,02	8
50	29,79	3,00	9

Table XLI - 4.20b X-ray powder reflections (up to 30 ° 2 θ) and intensities (normalized) of Suc2 = succinate, form II

	2 θ [°]	d [Å]	I/I_o [%]
55	5,68	15,55	6

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I ₀ [%]
5	8,72	10,13	8
	9,34	9,46	26
	9,98	8,86	15
10	11,37	7,78	44
	12,74	6,94	12
	13,09	6,76	6
15	14,25	6,21	4
	14,79	5,99	24
	15,05	5,88	26
20	15,37	5,76	16
	16,13	5,49	11
	16,68	5,31	9
25	16, 92	5,24	20
	17,14	5,17	40
	18,28	4,85	14
30	18,70	4,74	66
	19,15	4,63	9
	19,40	4,57	13
35	20,01	4,43	100
	20,64	4,30	26
	21,12	4,20	32
40	21,66	4,10	10
	22,25	3,99	15
	22,85	3,89	10
45	23,14	3,84	22
	23,69	3,75	3
	23,86	3,73	3
50	24,45	3,64	2
	25,14	3,54	10
	25,45	3,50	4
55	25,92	3,44	18
	26,36	3,38	3
	27,18	3,28	19
	27,73	3,21	3
	28,35	3,15	7
	29,09	3,07	5
	29,71	3,01	13

Table XLII - 4.21 a X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Oxa3 = oxalate, form III

5	2 Θ [°]	d [Å]	I/I_o [%]
	4,57	19,30	62
	5,47	16,15	21
	9,13	9,68	91
10	9,88	8,95	91
	10,91	8,10	23
	11,23	7,88	21
15	12,17	7,27	5
	13,10	6,75	71
	13,89	6, 37	31
	14,49	6,11	25
20	15,47	5,72	11
	16,33	5,42	43
	17,00	5,21	49
25	17,42	5,09	27
	18, 52	4,79	21
	19,15	4,63	62
	19,92	4,45	100
30	20, 78	4,27	36
	21,25	4,18	28
	22,70	3,91	31
35	22,96	3,87	59
	23,44	3,79	18
	24,17	3,68	34
	25,01	3,56	16
40	25,42	3,50	20
	26,10	3,41	17
	27,03	3,30	24
45	27,36	3,26	42
	28,02	3,18	16
	29,38	3,04	11
50	29,81	2,99	21

Table XLIII - 4.21 b X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Oxa5 = oxalate, form V

55	2 Θ [°]	d [Å]	I/I_o [%]
	8,72	10,13	61

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I_o [%]
5	10,19	8,67	10
	10,74	8,23	20
	11,41	7,75	19
	12,20	7,25	30
10	13,45	6,58	3
	14,18	6,24	18
	15,26	5,80	22
	15,55	5,69	31
15	15,84	5,59	72
	16,17	5,48	65
	16,50	5,37	23
20	16,99	5,21	16
	17,25	5,14	17
	17,59	5,04	6
25	18,19	4,87	8
	18,42	4,81	10
	18,87	4,70	5
	19,65	4,51	4
30	20,22	4,39	7
	20,82	4,26	12
	21,75	4,08	67
35	22,30	3,98	25
	23,12	3,84	100
	23,57	3,77	13
	24,01	3,70	21
40	24,60	3,62	17
	25,21	3,53	25
	25,96	3,43	29
45	26,85	3,32	16
	27,92	3,19	13
	28,62	3,12	10
50	29,59	3,02	13

Table XLIV - 4.21c X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Oxa6 = oxalate, form VI

55	2 Θ [°]	d [Å]	I/I_o [%]
	5,51	16,02	19
	9,36	9,44	17

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I _o [%]
5	10,26	8,62	16
	11,12	7,95	46
	12,40	7,13	4
	13,07	6,77	100
10	13,71	6,45	21
	14,09	6,28	11
	15,57	5,69	1
15	16,12	5,49	51
	16,43	5,39	76
	17,18	5,16	26
	17,65	5,02	18
20	18,77	4,73	31
	19,09	4,65	82
	19,89	4,46	65
25	20,63	4,30	54
	21,59	4,11	23
	22,05	4,03	44
	23,02	3,86	10
30	23,74	3,74	39
	24,34	3,65	24
	25,32	3,51	26
35	26,36	3,38	22
	27,24	3,27	8
	28,86	3,09	8
	29,20	3,06	12
40	29,54	3,02	14
	29,94	2,98	21

45 **Table XLV - 4.22 X-ray powder reflections (up to 30° 2 Θ) and intensities (normalized) of Gen1 = gentisate, form I**

	2 Θ [°]	d [Å]	I/I _o [%]
	6,92	12,76	6
50	9,19	9,62	48
	9,61	9,20	3
	10,22	8,65	5
	10,46	8,45	5
55	11,98	7,38	44
	12,64	7,00	14
	13,28	6,66	38

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I _o [%]
5	13,74	6,44	70
	14,08	6,29	43
	14,50	6,10	7
	15,03	5,89	86
10	15,96	5,55	2
	16,39	5,40	9
	16,82	5,27	20
	17,52	5,06	6
15	18,37	4,82	85
	18,85	4,70	41
	19,73	4,50	87
20	20,52	4,32	33
	21,05	4,22	71
	21,35	4,16	100
	22,03	4,03	11
25	22,44	3,96	10
	22,99	3,87	38
	23,25	3,82	46
30	23,78	3,74	22
	24,12	3,69	17
	24,81	3,59	23
	25,03	3,55	25
35	25,49	3,49	24
	25,94	3,43	14
	26,68	3, 34	9
40	27,20	3,28	10
	27,70	3,22	7
	28,33	3,15	44
	28,83	3,09	36
45	29,22	3,05	8
	29,90	2,99	10

Table XLVI - 4.23a X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Cam2 = camphorate, form II

	2 Θ [°]	d [Å]	I/I _o [%]
55	5,48	16,12	8
	8,82	10,02	2
	9,18	9,62	2

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I _o [%]
5	9,49	9,31	3
	9,90	8,93	1
	10,38	8,51	10
10	10,88	8,12	46
	11,97	7,39	3
	13,18	6,71	3
15	13,99	6,32	25
	14,58	6,07	5
	14, 76	6,00	5
20	15,33	5,78	4
	15,86	5,58	25
	16,17	5,48	21
25	16,37	5,41	26
	16,92	5,24	13
	17,12	5,17	10
30	17,64	5,02	4
	17,92	4,94	2
	18,61	4,76	30
35	19,02	4,66	100
	19,36	4,58	12
	20,04	4,43	48
40	20,86	4,26	3
	22,82	3,89	7
	23,67	3,76	5
45	24,06	3,70	5
	24,31	3,66	10
	24,73	3,60	3
50	25,49	3,49	5
	25,81	3,45	5
	26,04	3,42	4
55	26,29	3,39	2
	26,90	3,31	1
	27,39	3,25	3
	28,30	3,15	3
	29,03	3,07	15
	29,50	3,03	4

EP 2 364 968 A1

Table XLVII - 4.23b X-ray powder reflections (up to $30^\circ 2\theta$) and intensities (normalized) of Cam2 = camphorate, form III

	$2\theta [^\circ]$	$d [\text{\AA}]$	$I/I_0 [\%]$
5	4,43	19,94	6
	6,95	12,71	15
	7,39	11,96	69
10	8,99	9,83	9
	9,51	9,30	55
	10,30	8,58	22
15	10,75	8,22	15
	12,21	7,25	3
	12,44	7,11	6
	13,06	6,78	20
20	13,48	6,56	5
	13,84	6,39	19
	14,13	6,26	11
25	14,83	5,97	100
	15,76	5,62	61
	16,26	5,45	27
	16,51	5,37	46
30	17,07	5,19	76
	17,42	5,09	34
	17,89	4,95	8
35	18,29	4,85	26
	18,56	4,78	13
	19,05	4,66	93
	20,05	4,42	14
40	20,82	4,26	7
	21,35	4,16	10
	21,74	4,08	26
45	22,34	3,98	12
	22,76	3,90	24
	23,25	3,82	8
	23,59	3,77	4
50	24,20	3,67	22
	24,46	3,64	20
	24,87	3,58	32
55	25,22	3,53	14
	25,71	3,46	4
	26,02	3,42	6

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I _o [%]
5	26,42	3,37	14
	27,11	3,29	5
	27,75	3,21	10
	28,04	3,18	8
10	28,24	3,16	6
	28,78	3,10	25

Table XLVIII - 4.24a X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Ben2 = benzoate, form II

	2 Θ [°]	d [Å]	I/I _o [%]
	3,43	25,72	34
20	6, 84	12,91	11
	8,01	11,03	48
	9,95	8,89	100
25	10,34	8,54	55
	10, 78	8,20	23
	11,40	7,76	5
	13,32	6,64	4
30	13,65	6,48	3
	14,47	6, 11	90
	14,84	5,96	24
35	15,30	5,79	25
	15,75	5,62	11
	16,23	5,46	66
	16,50	5,37	56
40	17,02	5,20	29
	17, 73	5, 00	77
	18,29	4,85	26
45	18,74	4,73	8
	19,18	4,62	20
	19,96	4,44	57
	20,79	4,27	14
50	21,25	4,18	38
	21,68	4,10	26
	22,50	3,95	43
55	22,97	3,87	27
	23,28	3,82	27
	23,66	3,76	31

EP 2 364 968 A1

(continued)

	2 θ [°]	d [Å]	I/I _o [%]
5	23,84	3,73	47
	24,12	3,69	15
	24,59	3,62	9
	24,97	3,56	21
10	25,26	3,52	50
	26,01	3,42	7
	26,33	3,38	10
	26,82	3,32	16
15	27,74	3,21	16
	28,23	3,16	6
	28,91	3,09	4
20	29,20	3,06	9

Table XLIX - 4.24b X-ray powder reflections (up to 30 ° 2 θ) and intensities (normalized) of Ben3 = benzoate, form III

	2 θ [°]	d [Å]	I/I _o [%]
25	6,65	13,28	27
	8,89	9,94	20
30	9,37	9,43	16
	9,85	8,97	6
	10,41	8,49	20
35	10,76	8,22	5
	11,50	7,69	17
	12,23	7,23	3
	12,62	7,01	4
40	13,14	6,73	8
	14,33	6,18	40
	14,68	6,03	4
45	15,73	5,63	71
	16,54	5,35	13
	17,46	5,08	20
	18,23	4,86	68
50	18,52	4,79	22
	18,77	4,72	30
	19,24	4,61	21
55	19,75	4,49	25
	20,27	4,38	100
	21,35	4,16	87

EP 2 364 968 A1

(continued)

	2θ [°]	d [Å]	I/I_0 [%]
5	22,04	4,03	8
	22,86	3,89	23
	23,03	3,86	16
10	24,26	3,67	56
	24,89	3,57	7
	25,44	3,50	7
15	25,87	3,44	16
	26,40	3,37	14
	27,10	3,29	8
20	27,37	3,26	9
	27,98	3,19	6
	28,57	3,12	9
25	29,09	3,07	5
	29,59	3,02	16
	29,96	2,98	22

Table L - 4.25a X-ray powder reflections (up to 30 ° 2 θ) and intensities (normalized) of Sac3 = saccharinate, form III

	2θ [°]	d [Å]	I/I_0 [%]
30	5,48	16,11	7
	7,35	12,02	22
	8,36	10,57	15
35	8,95	9,87	8
	10,21	8,66	11
	10,56	8,37	4
40	11,03	8,01	9
	11,30	7,83	5
	11,54	7,66	5
45	12,79	6,91	13
	13,93	6,35	5
	14,23	6,22	7
50	14,72	6,02	22
	14,87	5,95	19
	16,09	5,50	13
55	16,47	5,38	22
	16,77	5,28	11
	17,36	5,10	10
	17,72	5,00	21

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I₀ [%]
5	18,58	4,77	17
	18,83	4,71	10
	19,27	4,60	27
	19,71	4,50	100
10	20,13	4,41	28
	20,49	4,33	23
	20,85	4,26	25
15	21,51	4,13	24
	21,86	4,06	16
	22,59	3,93	17
	22,97	3,87	16
20	23,87	3,73	18
	24,31	3,66	11
	25,00	3,56	15
25	25,44	3,50	17
	26,78	3,33	4
	27,31	3,26	7
	28,37	3,14	6
30	29,15	3,06	22
	29,60	3,02	13

35 **Table LI - 4.25b X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Sac5 = saccharinate, form V**

	2 Θ [°]	d [Å]	I/I₀ [%]
	7,00	12,62	8
40	12,01	7,36	5
	12,46	7,10	5
	12,90	6,86	12
45	13,40	6,60	6
	13,86	6,39	49
	14,19	6,23	20
	15,15	5,84	50
50	16,09	5,50	13
	17,20	5,15	11
	17,57	5,04	10
55	18,13	4,89	31
	18,33	4,84	18
	18,60	4,77	45

EP 2 364 968 A1

(continued)

	2θ [°]	d [Å]	I/I_0 [%]
5	19,08	4,65	21
	19,39	4,57	27
	19,89	4,46	33
10	20,66	4,30	100
	21,34	4,16	20
	22,13	4,01	25
15	22,68	3,92	10
	23,20	3,83	20
	23,84	3,73	9
20	24,31	3,66	11
	25,00	3,56	24
	25,41	3,50	10
25	26,71	3,33	8
	27,38	3,25	11
	27,59	3,23	15
30	28,13	3,17	7
	28,64	3,11	13
	29,31	3,04	6
	29,59	3,02	5

Table LII - 4.26 X-ray powder reflections (up to $30^\circ 2\theta$) and intensities (normalized) of Sal1 = salicylate, form I

	2θ [°]	d [Å]	I/I_0 [%]
35	3,46	25,49	52
	6,89	12,81	11
	8,56	10,32	39
40	10,48	8,44	100
	11,72	7,55	12
	12,91	6,85	15
45	13,38	6,61	16
	13,81	6,41	5
	14,13	6,26	10
50	15,26	5,80	57
	15,70	5,64	67
	16,33	5,42	55
55	17,18	5,16	53
	17,47	5,07	28
	17,92	4,95	18
	18,47	4,80	42

EP 2 364 968 A1

(continued)

	2θ [°]	d [Å]	I/I_0 [%]
5	18,77	4,72	57
	19,17	4,63	46
	19,78	4,48	49
	21,39	4,15	72
10	21,86	4,06	16
	22,47	3,95	68
	23,27	3,82	14
	23,62	3,76	10
15	24,12	3,69	5
	24,63	3,61	44
	25,28	3,52	63
20	26,05	3,42	17
	26,50	3,36	10
	26,88	3,31	8
	27,54	3,24	26
25	27,91	3,19	16
	28,25	3,16	23
	29,16	3,06	22
30	29,34	3,04	21
	29,70	3,01	14

Table LIII - 4.27a X-ray powder reflections (up to 30° 2θ) and intensities (normalized) of L-Asp1 = L-aspartate, form I

	2θ [°]	d [Å]	I/I_0 [%]
	4,90	18,02	6
40	9,00	9,82	52
	9,40	9,41	4
	9,80	9,02	3
45	10,25	8,62	6
	11,19	7,90	4
	11,60	7,62	12
	12,74	6,95	6
50	13,66	6,48	2
	14,02	6,31	5
	14,35	6,17	3
55	14,68	6,03	4
	15,18	5,83	13
	15,37	5,76	11

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I _o [%]
5	15,90	5,57	20
	16,17	5,48	22
	17,51	5,06	43
	18,04	4,91	6
10	18,25	4,86	6
	18,83	4,71	7
	19,30	4,60	6
	19,67	4,51	12
15	20,62	4,30	100
	21,30	4,17	33
	21,76	4,08	4
20	22,63	3,93	28
	23,38	3,80	11
	23,73	3,75	8
25	24,57	3,62	6
	24,88	3,58	11
	25,15	3,54	14
	25,69	3,47	4
30	26,07	3,41	3
	27,15	3,28	11
	27,81	3,21	5
35	28,07	3,18	4
	28,62	3,12	2
	29,02	3,07	2
	29,42	3,03	7
40	30,06	2,97	10

Table LIV - 4.27b X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of L-Asp2 = L-aspartate, form II

	2 Θ [°]	d [Å]	I/I _o [%]
45	6,55	13,48	33
	9,06	9,75	23
50	9,85	8,97	4
	10,06	8,79	2
	10,79	8,20	11
55	11,25	7,86	11
	11,61	7,62	24
	12,22	7,24	7

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I_o [%]
5	12,66	6,98	4
	13,07	6,77	4
	14,12	6,27	5
	14,95	5,92	3
10	15,35	5,77	19
	16,70	5,30	47
	16,94	5,23	78
	17,62	5,03	100
15	17,94	4,94	63
	18,16	4,88	24
	19,11	4,64	18
20	19,73	4,50	73
	20,16	4,40	58
	21,05	4,22	3
	21,21	4,18	4
25	21,68	4,10	34
	22,06	4,03	5
	22,71	3,91	15
30	23,34	3,81	34
	23,70	3,75	9
	24,15	3,68	6
	24,55	3,62	4
35	24,90	3,57	3
	25,51	3,49	18
	26,31	3,38	15
40	26,91	3,31	16
	27,34	3,26	3
	27,81	3,21	12
	28,20	3,16	17
45	28,50	3,13	7
	28,78	3,10	13
	29,52	3,02	5
50	29,86	2,99	6

Table LV - 4.28a X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Asc1 = ascorbate, form I

55	2 Θ [°]	d [Å]	I/I_o [%]
	3,74	23,60	6

EP 2 364 968 A1

(continued)

	2 θ [°]	d [Å]	I/I_o [%]
5	4,48	19,69	10
	5,90	14,96	6
	8,65	10,22	100
	9,01	9,81	21
10	9,51	9,29	8
	10,63	8,31	7
	11,53	7,67	8
	11,91	7,43	9
15	12,40	7,13	6
	12,71	6,96	9
	13,39	6,61	34
20	14,73	6,01	6
	15,20	5,82	11
	15,60	5,67	8
25	16,46	5,38	16
	17,15	5,17	29
	17,63	5,03	23
	18,47	4,80	33
30	19,04	4,66	17
	20,05	4,42	24
	20,79	4,27	47
35	21,03	4,22	43
	21,55	4,12	83
	22,75	3,91	35
	23,42	3,80	14
40	23,94	3,71	27
	25,78	3,45	7
	27,03	3,30	10
45	27,91	3,19	16
	28,55	3,12	7

Table LVI - 4.28b X-ray powder reflections (up to 30 ° 2 θ) and intensities (normalized) of Asc3 = ascorbate, form III

	2 θ [°]	d [Å]	I/I_o [%]
50	4,46	19,81	5
	7,48	11,81	9
55	8,67	10,20	28
	9,27	9,53	21

EP 2 364 968 A1

(continued)

	2 Θ [°]	d [Å]	I/I _o [%]
5	9,99	8,85	9
	10,27	8,61	10
	10,78	8,20	8
	11,07	7,99	8
10	11, 70	7,56	19
	12,05	7,34	9
	12,59	7,03	9
	12,91	6,85	22
15	13,29	6,66	10
	13,67	6,47	14
	14,06	6,29	5
	15,04	5,89	9
20	15,41	5,74	12
	15,44	5, 73	11
	16,07	5,51	33
	16,50	5,37	14
25	17,26	5,13	48
	17,81	4,97	37
	18,57	4,77	100
	19,00	4,67	77
30	19,63	4,52	29
	20,11	4,41	49
	20,61	4,31	24
	21,07	4,21	24
35	21,70	4,09	30
	22,34	3,98	32
	22,78	3,90	15
	23,23	3,83	29
40	24,05	3,70	17
	24,43	3,64	9
	25,35	3,51	14
	25,78	3,45	8
45	26,30	3,39	12
	26,75	3,33	14
	27,60	3,23	13
	28,07	3,18	16
50	29,04	3,07	14

Table LVII - 4.28c X-ray powder reflections (up to 30 ° 2 Θ) and intensities (normalized) of Asc4 = ascorbate, form IV

	2 Θ [°]	d [Å]	I/I_o [%]
5	7,53	11,73	13
	8,02	11,02	14
	8,58	10,30	38
10	8,72	10,13	37
	9,20	9,61	42
	10,32	8,57	20
15	10,82	8,17	21
	11,69	7,57	25
	12,05	7,34	21
	12,99	6,81	20
20	13,30	6,65	19
	13,68	6,47	24
	14,88	5,95	18
25	15,43	5,74	21
	16,12	5,49	43
	17,26	5,13	51
	17,56	5,05	26
30	17,85	4,96	28
	18,58	4, 77	100
	19,09	4,65	87
35	19,61	4, 52	60
	20,15	4,40	53
	21,06	4,21	45
	21,68	4,10	57
40	22,36	3,97	36
	22,87	3,89	37
	23,22	3,83	34
45	23,89	3,72	21
	25,42	3,50	13
	26,28	3,39	11
	26,75	3,33	12
50	27,03	3,30	12
	27,43	3,25	12
	27,98	3,19	21
55	28,81	3,10	8
	29,15	3,06	11
	29,85	2,99	12

[0025] Thus, in accordance with one preferred embodiment, the present invention relates to the following salts and/or crystalline forms and/or crystalline salt forms of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone:

- 5 Crystalline 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, in particular in hemihydrated form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α , β , γ and of the cell volume V as given in above Table 3.1;
- 10 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone chloride, in particular in crystalline anhydrous Form I as characterized in above Table 2;
- 15 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone chloride, in particular in crystalline hydrated Form II as characterized in above Table 2;
- 20 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone bromide, in particular in crystalline hydrated Form II, more particularly in the form of its trihydrate, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α , β , γ and of the cell volume V as given in above Table 3.2;
- 25 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone bromide, in particular in crystalline anhydrous Form VII as characterized in above Table 2;
- 30 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone bromide, in particular in crystalline anhydrous Form VIII as characterized in above Table 2;
- 35 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone phosphate, in particular in crystalline Form I as characterized in above Table 2;
- 40 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone phosphate, in particular in crystalline hydrated Form II, more particularly in its 3,5 - hydrate form, characterized by a monoclinic elementary cell with single crystal X-ray characteristic values of a, b, c, β and of the cell volume V as given in above Table 3.3;
- 45 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone sulfate, in particular in its crystalline hydrated Form I as characterized in above Table 2;
- 50 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone sulfate, in particular in its crystalline Form V as characterized in above Table 2;
- 55 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone sulfate, in particular in its crystalline hydrated Form VI as characterized in above Table 2;
- 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone sulfate, in particular in its crystalline hydrated Form VII as characterized in above Table 2;
- 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone methanesulfonate, in particular in crystalline hydrated Form I, more particularly in its hemihydrate form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α , β , γ and of the cell volume V as given in above Table 3.4;
- 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone ethanedisulfonate, in particular in its crystalline Form I as characterized in above Table 2;
- Bis[3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone]ethanedisulfonate, in particular in its crystalline Form I as characterized in above Table 2;
- 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methox-

ycarbonyl-2-indolinone ethanedisulfonate, in particular in its crystalline Form II as characterized in above Table 2;

Bis{3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}ethanedisulfonate, in particular in its crystalline Form II as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone ethanedisulfonate, in particular in its crystalline hydrated Form III as characterized in above Table 2;

Bis {3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}ethanedisulfonate, in particular in its crystalline hydrated Form III as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone ethanedisulfonate, in particular in its crystalline Form V as characterized in above Table 2;

Bis{3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}ethanedisulfonate, in particular in its crystalline Form V as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone ethanedisulfonate, in particular in its crystalline Form VI as characterized in above Table 2;

Bis{3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}ethanedisulfonate, in particular in its crystalline Form VI as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone isethionate, in particular in crystalline anhydrous Form I, characterized by a monoclinic elementary cell with single crystal X-ray characteristic values of a, b, c, β and of the cell volume V as given in above Table 3.5;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone isethionate, in particular in its crystalline Form II as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone isethionate, in particular in its crystalline Form IV as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone isethionate, in particular in crystalline hydrated Form V, more particularly in its dihydrate form, characterized by a monoclinic elementary cell with single crystal X-ray characteristic values of a, b, c, β and of the cell volume V as given in above Table 3.5;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzenesulfonate, in particular in crystalline hydrated Form I, more particularly in its trihydrate form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α , β , γ and of the cell volume V as given in above Table 3.7;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzenesulfonate, in particular in its crystalline Form III as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzenesulfonate, in particular in its crystalline Form V as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone tosylate, in particular in crystalline hydrated Form I, more particularly in its monohydrate form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α , β , γ and

of the cell volume V as given in above Table 3.8;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone tosylate, in particular in crystalline hydrated Form II, more particularly in its trihydrate form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α , β , γ and of the cell volume V as given in above Table 3.9;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorsulfonate, in particular in its crystalline anhydrous Form II as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorsulfonate, in particular in crystalline anhydrous Form III, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α , β , γ and of the cell volume V as given in above Table 3.10;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorsulfonate, in particular in crystalline solvated Form V, more particularly in its hemisolvated form with propionitrile, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α , β , γ and of the cell volume V as given in above Table 3.11;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorsulfonate, in particular in crystalline solvated Form XII, more particularly in its hemisolvated form with 1,2-dimethoxyethane, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α , β , γ and of the cell volume V as given in above Table 3.12;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone naphthalene-1,5-disulfonate, in particular in its crystalline Form III as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone naphthalene-1,5-disulfonate, in particular in its crystalline hydrated Form V as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone citrate, in particular in its crystalline anhydrous Form I as characterized in above Table 2;

Bis(3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone) citrate, in particular in its crystalline anhydrous Form I as characterized in above Table 2;

Bis(3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone) citrate, in particular in its crystalline hydrated Form II, more particularly in its dihydrated form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α , β , γ and of the cell volume V as given in above Table 3.13;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone D-tartrate, in particular in its crystalline hydrated Form I as characterized in above Table 2;

Bis(3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone) D-tartrate, in particular in its crystalline Form II as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-tartrate, in particular in its crystalline hydrated Form I as characterized in above Table 2;

Bis(3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone) L-tartrate, in particular in its crystalline Form II as characterized in above Table 2;

Bis{3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}fumarate, in particular in its crystalline hydrated Form I as characterized in above Table 2;

Bis{3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone} fumarate, in particular in its crystalline anhydrous Form III as characterized in above Table 2;

Bis{3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}maleate, in particular in its crystalline anhydrous Form I as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-lactate, in particular in crystalline hydrated Form I, more particularly in its 2.5-hydrated form, characterized by a monoclinic elementary cell with single crystal X-ray characteristic values of a, b, c, β and of the cell volume V as given in above Table 3.14;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone glycolate, in particular in its crystalline hydrated Form I as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone glycinate, in particular in its crystalline Form I as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-malate, in particular in its crystalline hydrated Form I as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-malate, in particular in its crystalline Form II as characterized in above Table 2;

Bis{3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}L-malate, in particular in its crystalline Form II as characterized in above Table 2;

Bis {3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}L-malate, in particular in its crystalline hydrated Form III, more particularly in its tetrahydrated form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α , β , γ and of the cell volume V as given in above Table 3.15;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone D-malate, in particular in its crystalline hydrated Form I as characterized in above Table 2;

Bis{3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}D-malate, in particular in its crystalline Form III as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone malonate, in particular in its crystalline hydrated Form I as characterized in above Table 2;

Bis{3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}malonate, in particular in its crystalline hydrated Form I as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone malonate, in particular in its crystalline hydrated Form II as characterized in above Table 2;

Bis {3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}malonate, in particular in its crystalline hydrated Form II as characterized in above Table 2;

Bis {3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-

methoxycarbonyl-2-indolinone}malonate, in particular in its crystalline hydrated and/or solvated Form III as characterized in above Table 2;

Bis {3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}malonate, in particular in its crystalline Form IV as characterized in above Table 2;

Bis {3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}malonate, in particular in its crystalline Form VI as characterized in above Table 2;

Bis {3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}succinate, in particular in its crystalline hydrated Form I as characterized in above Table 2;

Bis {3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}succinate, in particular in its crystalline hydrated Form II as characterized in above Table 2;

Bis {3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}succinate, in particular in its crystalline hydrated Form III, more particularly in its hexahydrated form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α , β , γ and of the cell volume V as given in above Table 3.16;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone oxalate, in particular in its crystalline hydrated Form III as characterized in above Table 2;

Bis {3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}oxalate, in particular in its crystalline hydrated Form III as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone oxalate, in particular in its crystalline Form V as characterized in above Table 2;

Bis {3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}oxalate, in particular in its crystalline Form V as characterized in above Table 2;

Bis(3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}oxalate, in particular in its crystalline hydrated Form VI as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone gentisate, in particular in its crystalline hydrated Form I as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone gentisate, in particular in crystalline hydrated Form XI, more particularly in its hemihydrated form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α , β , γ and of the cell volume V as given in above Table 3.17;

3-Z-[1-(4-(N-((4-methyl-piprazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorate, in particular in its crystalline hydrated Form II as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone camphorate, in particular in its crystalline Form III as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzoate, in particular in its crystalline hydrated Form II as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone benzoate, in particular in its crystalline Form III as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone mandelate, in particular in crystalline hydrated Form I, more particularly in its monohydrated form, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α , β , γ and of the cell volume V as given in above Table 3.18;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone saccharinate, in particular in its crystalline Form III as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone saccharinate, in particular in its crystalline hydrated Form V as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone salicylate, in particular in its crystalline Form I as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone salicylate, in particular in crystalline anhydrous Form II, characterized by a triclinic elementary cell with single crystal X-ray characteristic values of a, b, c, α , β , γ and of the cell volume V as given in above Table 3.19;

Bis {3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}L-aspartate, in particular in its crystalline hydrated Form I as characterized in above Table 2;

Bis {3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}L-aspartate, in particular in its crystalline Form II as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone xinafoate, in particular in crystalline hydrated Form I, more particularly in its monohydrate form, characterized by a monoclinic elementary cell with single crystal X-ray characteristic values of a, b, c, β and of the cell volume V as given in above Table 3.20;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone ascorbate, in particular in its crystalline Form I as characterized in above Table 2;

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone ascorbate, in particular in its crystalline Form III as characterized in above Table 2; and

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone ascorbate, in particular in its crystalline Form IV as characterized in above Table 2.

[0026] A further object of the present invention is the use of the above salts and crystalline salt forms as medicament.

[0027] A further object of the present invention is the use of the above salts and crystalline salt forms as medicament for the treatment or prevention of the following diseases.

[0028] The diseases which can be treated by the salts and crystal salt forms of the compound of formula (I) in accordance with the present invention are all kind of diseases in which cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis are involved, which can be of oncological nature such as all types of malignant neoplasias or cancers, or of non-oncological nature, such as diabetic retinopathy, rheumatoid arthritis, or psoriasis.

[0029] Among cancers, selected specific target indications are solid tumours, such as urogenital cancers (such as prostate cancer, renal cell cancers, bladder cancers), gynecological cancers (such as ovarian cancers, cervical cancers, endometrial cancers), lung cancer, gastrointestinal cancers (such as colorectal cancers, pancreatic cancer, gastric cancer, oesophageal cancers, hepatocellular cancers, cholangiocellular cancers), head and neck cancer, malignant mesothelioma, breast cancer, malignant melanoma or bone and soft tissue sarcomas, and haematologic neoplasias, such as multiple myeloma, acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome and acute lymphoblastic leukemia. Of special interest is the treatment of hormone sensitive or hormone refractory prostate cancer, ovarian carcinoma, non small cell lung cancer, small cell lung cancer, or multiple myeloma. Preferably, the underlying mechanism by which the above-mentioned diseases may be treated is via antagonism of at least one receptor selected from VEGFR 1 to 3, PDGFR α and β , FGFR1, 2 and 3, EGFR, HER2, IGF1R, HGFR, c-Kit, or a src tyrosine kinase family member.

[0030] In a further embodiment, the diseases which can be treated by the salts and crystal salt forms of the compound

of formula (I) in accordance with the present invention are also diseases which result from aberrant activity of the following tyrosine kinases: ABL, FGFR3, FLT3 and RET. Such diseases are, for example, Kidney Wilm's tumor, soft tissue osteosarcoma, glioblastoma multiforme, Ph+ leukemias such as chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL), epithelial cancers such as bladder and cervix cancers, multiple myeloma, hepatocellular carcinoma, skeletal abnormalities such as achondroplasia and hypochondroplasia, leukemias including acute myeloid leukemia (AML), AML with trilineage myelodysplasia (AML/TMDS), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), cancers of the nerve tissue such as neuroblastoma, multiple endocrine neoplasias type 2A and 2B (MEN2A and MEN2B), familial medullary thyroid carcinomas (FMTTC), papillary thyroid carcinomas (PTC) and breast cancer.

[0031] In yet another embodiment, the diseases which may be treated with the salts or crystal salt forms of the compound of formula (I) in accordance with the present invention are immunologic disease or pathological condition involving an immunologic component. Such diseases are, for example, autoimmune diseases, for instance inflammatory diseases having an autoimmune component such as inflammatory diseases selected from inflammatory bowel disease (e.g. colitis ulcerosa and Morbus Crohn), rheumatoid arthritis, glomerulonephritis and lung fibrosis, psoriasis, psoriasis arthritis, hypersensitivity reactions of the skin, atherosclerosis, restenosis, asthma, multiple sclerosis and type 1 diabetes, and indications which need immunosuppressant therapy, for instance prevention or therapy of tissue or organ transplant rejection. Preferably, the underlying mechanism by which the above-mentioned diseases may be treated is via antagonism of the Lck tyrosine kinase, a tyrosine kinase belonging to the src family.

[0032] It has further been surprisingly found that the salts or crystal salt forms of the compound of formula (I) in accordance with the present invention are suitable for the treatment of specific fibrotic diseases selected from the group consisting of fibrosis and remodeling of lung tissue in chronic obstructive pulmonary disease, fibrosis and remodeling of lung tissue in chronic bronchitis, fibrosis and remodeling of lung tissue in emphysema, lung fibrosis and pulmonary diseases with a fibrotic component, fibrosis and remodeling in asthma, fibrosis in rheumatoid arthritis, virally induced hepatic cirrhosis, radiation-induced fibrosis, post angioplasty restenosis, chronic glomerulonephritis, renal fibrosis in patients receiving cyclosporine and renal fibrosis due to high blood pressure, diseases of the skin with a fibrotic component, and excessive scarring. Amongst these diseases, preferred diseases which may be treated with the salts or crystal salt forms of the compound of formula (I) in accordance with the present invention are lung fibrosis and pulmonary diseases with a fibrotic component selected from idiopathic pulmonary fibrosis, giant cell interstitial pneumonia, sarcoidosis, cystic fibrosis, respiratory distress syndrome, drug-induced lung fibrosis, granulomatosis, silicosis, asbestosis, systemic scleroderma, the virally induced hepatic cirrhosis selected from hepatitis C induced hepatic cirrhosis, and the diseases of the skin with a fibrotic component selected from scleroderma, sarcoidosis and systemic lupus erythematosus.

[0033] Thus, the present invention further relates to the use of the salts and crystal salt forms of the compound of above formula (I) for the preparation of a medicament for the treatment or prevention of the above-mentioned fibrotic diseases.

[0034] Within the meaning of the present invention, the treatment of the diseases may also be via simultaneous, separate or sequential co-administration of effective amounts of one or more salts and crystal salt forms of the compound of formula (I) in accordance with the present invention and at least a further chemotherapeutic or naturally occurring, semi-synthetic or synthetic therapeutic agent, in the form of a combined preparation, which if necessary may optionally be adapted for a co-treatment with radiotherapy or radio-immunotherapy.

[0035] The present invention also relates to a process for the treatment of the above-mentioned diseases, characterized in that one or more of the above-mentioned salts or crystal salt forms of the compound of formula (I) are administered in therapeutically effective amounts to a patient in need thereof

[0036] The present invention further relates to processes for the treatment of the aforementioned diseases, characterized in that one or more of the above-mentioned salts or crystal salt forms of the compound of formula (I) are administered once or several times a day or once or several times a week in therapeutically effective amounts.

[0037] The present invention also relates to pharmaceutical compositions comprising the above-mentioned salts or crystalline salt forms.

[0038] In the treatment of the aforementioned diseases, the physicochemical properties of a drug substance may influence decisively stability, usefulness and efficacy of the formulation. In this respect the salts or crystal salt forms of the compound of formula (I) in accordance with the present invention show advantageous properties not yet disclosed in the art.

[0039] Suitable preparations for the pharmaceutical compositions in accordance with the present invention include for example tablets, capsules, suppositories, solutions, - particularly solutions for injection (s.c., i.v., i.m.) and infusion - elixirs, emulsions or dispersible powders. The proportion of the pharmaceutically active compound(s) should be in the range from 0.01 to 90 wt.-%, preferably 0.1 to 50 wt.-% of the composition as a whole, i.e. in amounts which are sufficient to achieve the dosage necessary to achieve a therapeutic effect. If necessary the doses specified may be given several times a day.

[0040] Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for

example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as maize starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.

[0041] Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number of layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.

[0042] Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.

[0043] Solutions for injection and infusion are prepared in the usual way, e.g. with the addition of isotonic agents, preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or dispersants, whilst if water is used as the diluent, for example, organic solvents may optionally be used as solvating agents or dissolving aids, and transferred into injection vials or ampoules or infusion bottles.

[0044] Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.

[0045] Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.

[0046] Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose) emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulphate).

[0047] The preparations are administered by the usual methods, preferably by oral route, by injection or transdermally. For oral administration the tablets may of course contain, apart from the abovementioned carriers, additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gelatine and the like. Moreover, lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be used at the same time for the tableting process. In the case of aqueous suspensions the active substances may be combined with various flavour enhancers or colourings in addition to the excipients mentioned above.

[0048] For parenteral use, solutions of the active substances with suitable liquid carriers may be used.

[0049] The dosage for intravenous use is from 1 - 1000 mg per hour, preferably between 5 and 500 mg per hour.

[0050] However, it may sometimes be necessary to depart from the amounts specified, depending on the body weight, the route of administration, the individual response to the drug, the nature of its formulation and the time or interval over which the drug is administered. Thus, in some cases it may be sufficient to use less than the minimum dose given above, whereas in other cases the upper limit may have to be exceeded. When administering large amounts it may be advisable to divide them up into a number of smaller doses spread over the day.

[0051] The following examples of pharmaceutical formulations illustrate the present invention without representing a limitation of its scope.

1. Coated tablet containing 75 mg of active substance

[0052]

Composition : 1 tablet core contains

active substance	75.0 mg
calcium phosphate	131.0 mg
polyvinylpyrrolidone	10.0 mg
carboxymethylcellulose sodium	10.0 mg
silicon dioxide	2.5 mg
magnesium stearate	1.5 mg

EP 2 364 968 A1

(continued)

230.0 mg

5 Preparation (direct compression):

[0053] The active substance is mixed with all components, sieved and compressed in a tablet-making machine to form tablets of the desired shape.

10 Weight of core: 230 mg
Appearance of core: 9 mm, biconvex

[0054] The tablet cores thus produced are coated with a film consisting essentially of hydroxypropylmethylcellulose.

15 Weight of coated tablet: 240 mg.

2. Tablet containing 100 mg of active substance

20 **[0055]**

Composition : 1 tablet contains	
active substance	100.0 mg
lactose	80.0 mg
corn starch	34.0 mg
hydroxypropylmethylcellulose	4.0 mg
magnesium stearate	2.0 mg
	220.0 mg

30

Preparation (wet granulation):

[0056] The active substance, lactose and starch are mixed together and uniformly moistened with an aqueous solution of the hydroxypropylmethylcellulose. After the moist composition has been screened (2.0 mm mesh size) and dried in a rack-type drier at 50°C it is screened again (1.5 mm mesh size) and the lubricant is added. The finished mixture is compressed to form tablets.

35

40 Weight of tablet: 220 mg
Appearance of tablet: 10 mm, flat faced with bevelled edges and breaking notch on one side

3. Tablet containing 150 mg of active substance

[0057]

45

Composition: 1 tablet contains	
active substance	150.0 mg
lactose	85.0 mg
microcrystalline cellulose	40.0 mg
polyvinylpyrrolidone	10.0 mg
silicon dioxide	10.0 mg
magnesium stearate	5.0 mg
	300.0 mg

55

EP 2 364 968 A1

Preparation (dry granulation):

[0058] The active substance mixed with lactose, polyvinylpyrrolidone, and parts of the microcrystalline cellulose, magnesium stearate is compacted e.g. on a roller compactor. The ribbons are broken up in fine granules through a screen with a mesh size of 0.8 mm. After subsequent sieving through a screen with a mesh size of 0.5 mm and blending with the remaining components, tablets are pressed from the mixture.

Weight of tablet: 300 mg
Appearance of tablet: 10 mm, flat

4. Hard gelatine capsule containing 150 mg of active substance

[0059]

Composition: 1 capsule contains	
active substance	150.0 mg
lactose	85.0 mg
microcrystalline cellulose	40.0 mg
polyvinylpyrrolidone	10.0 mg
silicon dioxide	10.0 mg
magnesium stearate	5.0 mg
	300.0 mg

Preparation:

[0060] The active substance mixed with lactose, polyvinylpyrrolidone, and parts of the microcrystalline cellulose, magnesium stearate is compacted e.g. on a roller compactor. The ribbons are broken up in fine granules through a screen with a mesh size of 0.8 mm. After subsequent sieving through a screen with a mesh size of 0.5 mm and blending with the remaining components, the finished mixture is packed into size 1 hard gelatine capsules.

Capsule filling: approx. 300 mg
Capsule shell: size 1 hard gelatine capsule

5. Suppository containing 150 mg of active substance

[0061]

1 suppository contains:	
active substance	150.0 mg
polyethyleneglycol 1500	800.0 mg
polyethyleneglycol 6000	850.0 mg
polyoxyl 40 hydrogenated castor oil	200.0 mg
	2,000.0 mg

Preparation:

[0062] After the suppository mass has been melted the active substance is homogeneously distributed therein and the melt is poured into chilled moulds.

6. Suspension containing 50 mg of active substance

[0063]

EP 2 364 968 A1

100 ml of suspension contains:

active substance	1.00 g
carboxymethylcellulose sodium	0.10 g
methyl p-hydroxybenzoate	0.05 g
propyl p-hydroxybenzoate	0.01 g
glucose	10.00 g
glycerol	5.00 g
70% sorbitol solution	20.00 g
flavouring	0.30 g
dist. water	ad 100 ml

Preparation:

[0064] The distilled water is heated to 70°C. The methyl and propyl p-hydroxybenzoates together with the glycerol and sodium salt of carboxymethylcellulose are dissolved therein with stirring. The solution is cooled to ambient temperature and the active substance is added and homogeneously dispersed therein with stirring. After the sugar, the sorbitol solution and the flavouring have been added and dissolved, the suspension is evacuated with stirring to eliminate air.

[0065] Thus, 5 ml of suspension contains 50 mg of active substance.

7. Ampoule containing 10 mg active substance

[0066]

Composition:

active substance	10.0 mg
0.01 N hydrochloric acid	q.s.
double-distilled water	ad 2.0 ml

Preparation:

[0067] The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic with sodium chloride, filtered sterile and transferred into a 2 ml ampoule.

8. Ampoule containing 50 mg of active substance

[0068]

Composition:

active substance	50.0 mg
0.01 N hydrochloric acid	q.s.
double-distilled water	ad 10.0 ml

Preparation:

[0069] The active substance is dissolved in the necessary amount of 0.01 N HCl, made isotonic with sodium chloride, filtered sterile and transferred into a 10 ml ampoule.

9. Capsule for powder inhalation containing 5 mg of active substance

[0070]

1 capsule contains:

active substance	5.0 mg
lactose for inhalation	15.0 mg

(continued)

20.0 mg

5 Preparation:

[0071] The active substance is mixed with lactose for inhalation. The mixture is packed into capsules in a capsule-making machine (weight of the empty capsule approx. 50 mg).

Weight of capsule: 70.0 mg

10 Size of capsule = size 3

10. Solution for inhalation for a hand-held nebuliser containing 2.5 mg active substance

[0072]

15

1 spray contains:

active substance 2.500 mg

benzalkonium chloride 0.001 mg

1N hydrochloric acid q.s.

20

ethanol/water (50/50) ad 15.000 mg

Preparation:

25

[0073] The active substance and benzalkonium chloride are dissolved in ethanol/water (50/50). The pH of the solution is adjusted with 1N hydrochloric acid. The resulting solution is filtered and transferred into suitable containers for use in hand-held nebulisers (cartridges).

Contents of the container: 4.5 g

30

Claims

1. Salt of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, which is selected from the group consisting of:

35

the 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone citrate;

the bis{3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone} citrate;

40

the 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone D-tartrate;

the bis{3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone} D-tartrate;

45

the 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-tartrate;

the bis{3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone} L-tartrate;

the 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-lactate;

50

the 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone glycolate;

the 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone gentisate;

55

the 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone mandelate; and

the 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone salicylate.

2. Crystalline salt form of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, which is selected from the group consisting of:

crystalline anhydrous 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone citrate;
 crystalline hydrated bis {3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone} citrate;
 crystalline hydrated 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone D-tartrate;
 crystalline bis {3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}D-tartrate;
 crystalline hydrated 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-tartrate;
 crystalline bis {3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}L-tartrate;
 crystalline hydrated 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-lactate;
 crystalline hydrated 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone glycolate;
 crystalline hydrated 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone gentisate;
 crystalline hydrated 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone mandelate;
 crystalline 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone salicylate; and
 crystalline anhydrous 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone salicylate.

3. Crystalline salt form of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone in accordance with claim 2, which is selected from the group consisting of:

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone citrate in crystalline anhydrous Form I;
 Bis{3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone} citrate in crystalline anhydrous Form I;
 Bis{3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone} citrate in crystalline dihydrated Form II;
 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone D-tartrate in crystalline hydrated Form I;
 Bis{3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}D-tartrate in crystalline Form II;
 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-tartrate in crystalline hydrated Form I;
 Bis{3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone}L-tartrate in crystalline Form II;
 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone L-lactate in crystalline 2,5-hydrated Form I;
 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone glycolate in crystalline hydrated Form I;
 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone gentisate in crystalline hydrated Form I;
 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone gentisate in crystalline hemihydrated Form XI;
 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone mandelate in crystalline monohydrated Form I;
 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone salicylate in crystalline Form I;

and

3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone salicylate in crystalline anhydrous Form II.

- 5 **4.** Salt or crystalline salt form in accordance with any one of claims 1 to 3 for its use as medicament.
- 5.** Pharmaceutical composition comprising a salt or a crystalline salt form in accordance with any one of claims 1 to 3, together with one or more inert carriers or diluents.

10

15

20

25

30

35

40

45

50

55

Fig. I




Fig. II




Fig. III




Fig. IV




Fig. V




Fig. VI




Fig. VII




Fig. VIII




Fig. IX




Fig. X




Fig. XI




Fig. XII




Fig. XIII




Fig. XIV




Fig. XV




Fig. XVI




Fig. XVII




Fig. XVIII




Fig. XIX




Fig. XX




Fig. XXI




Fig. XXII




Fig. XXIII




Fig. XXIV




Fig. XXV




Fig. XXVI




Fig. XXVII




Fig. XXVIII




Fig. XXIX




Fig. XXX




Fig. XXXI




Fig. XXXII




Fig. XXXIII




Fig. XXXIV




Fig. XXXV




Fig. XXXVI




Fig. XXXVII




Fig. XXXVIII




Fig. XXXIX




Fig. XL




Fig. XLI




Fig. XLII




Fig. XLIII




Fig. XLIV




Fig. XLV




Fig. XLVI




Fig. XLVII




Fig. XLVIII




Fig. XLIX




Fig. L




Fig. LI




Fig. LII




Fig. LIII




Fig. LIV




Fig. LV




Fig. LVI





Fig. LVII





EUROPEAN SEARCH REPORT

Application Number
EP 11 15 8863

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
Y	WO 2004/096224 A2 (BOEHRINGER INGELHEIM INT [DE]; BOEHRINGER INGELHEIM PHARMA [DE]; HILBE) 11 November 2004 (2004-11-11) * pages 28-32,64; compounds (T),MES(T),CL2(T) * * page 69 * * page 25, line 4 - line 20 *	1-5	INV. C07D209/34 A61K31/404 A61P35/04
Y,D	WO 01/27081 A (BOEHRINGER INGELHEIM PHARMA [DE]; HECKEL ARMIN [DE]; ROTH GERALD JUERG) 19 April 2001 (2001-04-19) * page 64, paragraph 2; compounds 473, 171 *	1-5	
A	WO 2004/013099 A1 (BOEHRINGER INGELHEIM PHARMA [DE]; ROTH GERALD JUERGEN [DE]; SIEGER PET) 12 February 2004 (2004-02-12) * claims *	1-5	
A	BERGE S M ET AL: "PHARMACEUTICAL SALTS", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 66, no. 1, 1 January 1977 (1977-01-01), pages 1-19, XP002552191, ISSN: 0022-3549, DOI: DOI:10.1002/JPS.2600660104 * page 1 - page 3 * * page 5, left-hand column *	1-5	TECHNICAL FIELDS SEARCHED (IPC) C07D A61P A61K
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 4 August 2011	Examiner Härtinger, Stefan
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

1
EPO FORM 1503 03.82 (P04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 11 15 8863

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	MORISSETTE SHERRY L ET AL: "HIGH-THROUGHPUT CRYSTALLIZATION: POLYMORPHS, SALTS, CO-CRYSTALS AND SOLCATES OF PHARMACEUTICAL SOLIDS", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 56, no. 3, 1 January 2004 (2004-01-01), pages 275-300, XP009072233, ISSN: 0169-409X, DOI: DOI:10.1016/J.ADDR.2003.10.020 * page 276 - page 277 * * page 285, right-hand column - page 287 * -----	1-5	
			TECHNICAL FIELDS SEARCHED (IPC)
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 4 August 2011	Examiner Härtinger, Stefan
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

1
EPO FORM 1503 03.82 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 11 15 8863

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

04-08-2011

Patent document cited in search report		Publication date	Patent family member(s)	Publication date			
WO 2004096224 A2		11-11-2004	AR 044114 A1	24-08-2005			
			AU 2004233576 A1	11-11-2004			
			AU 2010236075 A1	18-11-2010			
			BR PI0409919 A	25-04-2006			
			CA 2523868 A1	11-11-2004			
			CL 9002004 A1	04-03-2005			
			CN 1780627 A	31-05-2006			
			CO 5640112 A2	31-05-2006			
			EA 200900272 A1	30-10-2009			
			EC SP056132 A	01-03-2006			
			EP 1622619 A2	08-02-2006			
			HK 1091416 A1	17-12-2010			
			JP 4701159 B2	15-06-2011			
			JP 2006524634 A	02-11-2006			
			JP 2010202658 A	16-09-2010			
			KR 20060008945 A	27-01-2006			
			MX PA05011656 A	15-12-2005			
			NZ 543774 A	30-10-2009			
			PE 04632005 A1	18-07-2005			
			RS P20050802 A	31-12-2007			
			US 2008254040 A1	16-10-2008			
			US 2005043233 A1	24-02-2005			
			US 2011039863 A1	17-02-2011			
			US 2011136826 A1	09-06-2011			
			US 2011171289 A1	14-07-2011			
			UY 28287 A1	30-11-2004			

			WO 0127081 A		19-04-2001	AT 439342 T	15-08-2009
						AU 781939 B2	23-06-2005
						AU 1023301 A	23-04-2001
						BG 106587 A	31-01-2003
						BR 0014735 A	16-07-2002
CA 2387013 A1	19-04-2001						
CN 1391557 A	15-01-2003						
CO 5261488 A1	31-03-2003						
CZ 20021410 A3	17-07-2002						
DK 1224170 T3	07-12-2009						
EE 200200197 A	16-06-2003						
EP 1224170 A1	24-07-2002						
EP 2157081 A1	24-02-2010						
ES 2331459 T3	05-01-2010						
HK 1052505 A1	26-06-2009						
HR 20020306 A2	31-10-2003						
HU 0204587 A2	28-05-2003						
IL 148756 A	31-10-2007						
JP 4021664 B2	12-12-2007						

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 11 15 8863

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

04-08-2011

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0127081	A		JP 2003511441 A	25-03-2003
			JP 2007302697 A	22-11-2007
			KR 20070095996 A	01-10-2007
			MX PA02002799 A	27-02-2003
			NO 20021719 A	11-04-2002
			NZ 518489 A	27-05-2005
			PL 355433 A1	19-04-2004
			PT 1224170 E	01-10-2009
			SI 1224170 T1	31-12-2009
			SK 6462002 A3	06-08-2002
			TW I268922 B	21-12-2006

WO 2004013099	A1	12-02-2004	AR 040662 A1	13-04-2005
			AU 2003254376 A1	23-02-2004
			BR 0312811 A	19-04-2005
			CA 2493310 A1	12-02-2004
			CN 1671660 A	21-09-2005
			DE 10233500 A1	19-02-2004
			EC SP055571 A	18-04-2005
			EG 24562 A	25-10-2009
			EP 1527047 A1	04-05-2005
			HK 1078851 A1	07-03-2008
			HR 20050070 A2	31-12-2005
			IL 166405 A	18-11-2009
			JP 2005535684 A	24-11-2005
			KR 20050042139 A	04-05-2005
			MX PA04012785 A	08-06-2005
			NO 330486 B1	26-04-2011
			PE 07042004 A1	29-11-2004
			RS P20050046 A	21-09-2007
			TW I285635 B	21-08-2007
			UA 78352 C2	15-03-2007
			UY 27904 A1	27-02-2004
			ZA 200409814 A	22-02-2006

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 0127081 A [0002]
- WO 0413099 A [0003]
- WO 0417948 A [0005]